Search by Patent Identification
Patent | Data | Compounds | HGNC (for human-derived proteins) | Patent Title | Organization | Deposition | Downloads |
---|---|---|---|---|---|---|---|
US11225479 | 30 | 15 | HGNC:4852 HGNC:4853 | Bicyclic inhibitors of histone deacetylase | Alkermes, Inc. | 05/22/22 | 2D 3D TSV |
US11224601 | 979 | 813 | Compounds that inhibits MCL-1 protein | AMGEN INC. | 05/22/22 | 2D 3D TSV | |
US11225492 | 64 | 18 | HGNC:4852 HGNC:1771 HGNC:14064 | Heterocycles useful as anti-cancer agents | Hangzhou Innogate Pharma Co., Ltd. | 05/22/22 | 2D 3D TSV |
US11225469 | 284 | 275 | HGNC:8923 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | Whitehead Institute for Biomedical Research; Dana-Farber Cancer Institute, Inc.; The United States of America, as represented by the Secretary, Department of Health and Human Services | 05/22/22 | 2D 3D TSV |
US11225475 | 20 | 10 | HGNC:4852 HGNC:4853 | Substituted pyridines as inhibitors of histone deacetylase | Alkermes, Inc. | 05/22/22 | 2D 3D TSV |
US11225486 | 252 | 122 | HGNC:8978 HGNC:8977 | Tertiary alcohols as PI3K-γ inhibitors | Incyte Corporation | 05/22/22 | 2D 3D TSV |
US11220505 | 16 | 16 | HGNC:5302 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | Temple University-Of the Commonwealth System of Higher Education | 05/14/22 | 2D 3D TSV |
US11220494 | 294 | 137 | HGNC:1773 | Cyclin dependent kinase inhibitors | Pfizer Inc. | 05/14/22 | 2D 3D TSV |
US11220486 | 362 | 333 | HGNC:122 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY; SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE | 05/14/22 | 2D 3D TSV |
US11219618 | 24 | 23 | HGNC:8974 | Pyridylpyridone compounds | Sprint Bioscience AB | 05/14/22 | 2D 3D TSV |
US11220510 | 30 | 30 | HGNC:263 | Pyrrole tricyclic compounds as A2A / A2B inhibitors | Incyte Corporation | 05/14/22 | 2D 3D TSV |
US11220524 | 72 | 71 | HGNC:29652 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | Prelude Therapeutics Incorporated | 05/14/22 | 2D 3D TSV |
US11220509 | 528 | 218 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | MIRATI THERAPEUTICS, INC. | 05/14/22 | 2D 3D TSV | |
US11220518 | 98 | 93 | HGNC:9395 | Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors | PFIZER INC. | 05/14/22 | 2D 3D TSV |
US11220508 | 218 | 217 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 05/14/22 | 2D 3D TSV | |
US11214576 | 4 | 4 | HGNC:7056 | 2,3-dihydrofuro[2,3-b]pyridine compounds | Eli Lilly and Company | 05/08/22 | 2D 3D TSV |
US11214573 | 84 | 42 | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | Incyte Holdings Corporation; Incyte Corporation | 05/08/22 | 2D 3D TSV | |
US11214548 | 26 | 17 | HGNC:2160 HGNC:2159 | Cannabinoid receptor modulators | Arena Pharmaceuticals, Inc. | 05/08/22 | 2D 3D TSV |
US11214540 | 151 | 88 | Compositions for treating neurodegenerative diseases | Cognition Therapeutics, Inc. | 05/08/22 | 2D 3D TSV | |
US11214565 | 355 | 341 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. | 05/08/22 | 2D 3D TSV | |
US11213515 | 25 | 25 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC | 05/08/22 | 2D 3D TSV | |
US11214542 | 212 | 103 | HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. | 05/08/22 | 2D 3D TSV |
US11214554 | 66 | 52 | HGNC:6059 | Indoleamine 2,3-dioxygenase inhibitor, method for preparation and use thereof | NANJING HUAWE MEDICINE TECHNOLOGY GROUP CO., LTD. | 05/08/22 | 2D 3D TSV |
US11213525 | 22 | 21 | HGNC:7056 | Linear glycosidase inhibitors | Asceneuron SA | 05/08/22 | 2D 3D TSV |
US11214557 | 42 | 42 | HGNC:17038 | MAGL inhibitors | H. LUNDBECK A/S | 05/08/22 | 2D 3D TSV |
US11213520 | 16 | 16 | HGNC:1779 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | Boehringer Ingelheim International GmbH | 05/08/22 | 2D 3D TSV |
US11214574 | 49 | 49 | HGNC:29652 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | Prelude Therapeutics, Incorporated | 05/08/22 | 2D 3D TSV |
US11214563 | 53 | 52 | HGNC:4586 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV | 05/08/22 | 2D 3D TSV |
US11214566 | 18 | 7 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | Janssen Pharmaceutica NV | 05/08/22 | 2D 3D TSV | |
US11208411 | 72 | 32 | HGNC:11283 | Compositions and methods for treating parasitic diseases | The Regents of the University of California; Washington University | 05/03/22 | 2D 3D TSV |
US11208404 | 192 | 109 | Compounds useful as inhibitors of ALCAT 1 | PERENNA PHARMACEUTICALS, INC. | 05/03/22 | 2D 3D TSV | |
US11208414 | 151 | 80 | HGNC:8021 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. | 05/03/22 | 2D 3D TSV |
US11208418 | 5 | 5 | HGNC:7967 | Nitrogenous tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. | 05/03/22 | 2D 3D TSV |
US11208696 | 31 | 31 | HGNC:12401 | Prognostic biomarkers for TTK inhibitor chemotherapy | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. | 05/03/22 | 2D 3D TSV |
US11208423 | 20 | 20 | HGNC:8974 | Pyridinamine-pyridone and pyrimidinamine- pyridone compounds | Sprint Bioscience AB | 05/03/22 | 2D 3D TSV |
US11208403 | 267 | 121 | HGNC:7027 | Pyridone derivatives having tetrahydropyranylmethyl groups | Daiichi Sankyo Company, Limited | 05/03/22 | 2D 3D TSV |
US11208416 | 42 | 41 | HGNC:29652 | Selective inhibitors of protein arginine methytransterase 5 (PRMT5) | Prelude Therapeutics Incorporated | 05/03/22 | 2D 3D TSV |
US11208422 | 188 | 53 | HGNC:6283 HGNC:6278 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | Bayer Pharma Aktiengesellschaft; Bayer Aktiengesellschaft | 05/03/22 | 2D 3D TSV |
US11208415 | 416 | 376 | HGNC:6943 HGNC:992 HGNC:990 | Substituted indole Mcl-1 inhibitors | Vanderbilt University | 05/03/22 | 2D 3D TSV |
US11207302 | 21 | 20 | HGNC:6059 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | Incyte Corporation; Incyte Holdings Corporation | 05/02/22 | 2D 3D TSV |
US11208377 | 119 | 119 | HGNC:1607 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. | 05/02/22 | 2D 3D TSV |
US11208388 | 98 | 96 | HGNC:1133 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC | 05/02/22 | 2D 3D TSV |
US11207431 | 131 | 27 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | HDAC6 inhibitors and imaging agents | The General Hospital Corporation | 05/02/22 | 2D 3D TSV |
US11208381 | 336 | 55 | HGNC:8803 HGNC:3763 HGNC:6307 HGNC:8804 HGNC:3690 HGNC:3688 | Indole derivatives and their use as protein kinase inhibitors | RESPIVERT LIMITED | 05/02/22 | 2D 3D TSV |
US11207312 | 828 | 204 | Metallo-beta-lactamase inhibitors and methods of use thereof | Merck Sharp & Dohme Corp. | 05/02/22 | 2D 3D TSV | |
US11208399 | 224 | 117 | HGNC:5992 HGNC:11892 | NLRP3 inflammasome inhibitors | Novartis AG | 05/02/22 | 2D 3D TSV |
US11207298 | 596 | 595 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV | 05/02/22 | 2D 3D TSV | |
US11208400 | 567 | 526 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft | 05/02/22 | 2D 3D TSV | |
US11208384 | 2 | 1 | HGNC:12437 HGNC:4623 | Sulfinylpyridines and their use in the treatment of cancer | Oblique Therapeutics AB | 05/02/22 | 2D 3D TSV |
US11207325 | 709 | 243 | HGNC:3188 | Triazolopyrimidine compounds and uses thereof | Novartis AG | 05/02/22 | 2D 3D TSV |
US11203594 | 66 | 28 | HGNC:1773 | Anti-proliferative agents for treating PAH | Pfizer Inc. | 04/29/22 | 2D 3D TSV |
US11203595 | 52 | 13 | Aza-indazole compounds for use in tendon and/or ligament injuries | NOVARTIS AG | 04/29/22 | 2D 3D TSV | |
US11203574 | 302 | 247 | HGNC:6371 | Human plasma kallikrein inhibitors | BioCryst Pharmaceuticals, Inc. | 04/29/22 | 2D 3D TSV |
US11203586 | 38 | 37 | Iridinesulfonamide compound and use method thereof | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd.; Centaurus Biopharma Co., Ltd. | 04/29/22 | 2D 3D TSV | |
US11203600 | 326 | 281 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. | 04/29/22 | 2D 3D TSV | |
US11202743 | 22 | 14 | HGNC:3553 HGNC:2160 HGNC:2159 | Personal care compositions comprising fatty acid amide derivatives | Conopco, Inc. | 04/29/22 | 2D 3D TSV |
US11203591 | 304 | 302 | HGNC:6863 | Substituted 6-azabenzimidazole compounds | Gilead Sciences, Inc. | 04/29/22 | 2D 3D TSV |
US11203571 | 100 | 100 | HGNC:10582 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 04/29/22 | 2D 3D TSV |
US11203601 | 38 | 19 | HGNC:4617 HGNC:4616 | Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof | The Broad Institute, Inc.; Biogen MA Inc. | 04/29/22 | 2D 3D TSV |
US11198699 | 72 | 56 | HGNC:29652 | Compounds targeting PRMT5 | Aligos Therapeutics, Inc. | 04/25/22 | 2D 3D TSV |
US11198695 | 577 | 573 | HGNC:7045 | Fused ring derivative having MGAT-2 inhibitory activity | SHIONOGI & CO., LTD. | 04/25/22 | 2D 3D TSV |
US11197867 | 468 | 113 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Aminopyrimidinyl compounds | Pfizer Inc. | 04/24/22 | 2D 3D TSV |
US11197877 | 16 | 16 | HGNC:10718 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | GLYCOMIMETICS. INC. | 04/24/22 | 2D 3D TSV |
US11198681 | 192 | 115 | HGNC:18368 | Heteroaryl inhibitors of PAD4 | Padlock Therapeutics, Inc. | 04/24/22 | 2D 3D TSV |
US11198691 | 188 | 92 | HGNC:6371 HGNC:6357 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KalVista Pharmaceuticals Limited | 04/24/22 | 2D 3D TSV |
US11198680 | 42 | 13 | HGNC:10251 HGNC:10252 | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof | BioAxone BioSciences, Inc. | 04/24/22 | 2D 3D TSV |
US11192871 | 30 | 30 | HGNC:5302 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University-Of The Commonwealth System of Higher Education | 04/17/22 | 2D 3D TSV |
US11191762 | 118 | 111 | HGNC:339 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. | 04/17/22 | 2D 3D TSV |
USRE48841 | 739 | 377 | HGNC:4849 HGNC:4848 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | Janssen Pharmaceutica NV | 04/17/22 | 2D 3D TSV |
US11191732 | 9 | 8 | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy | THE JOHNS HOPKINS UNIVERSITY | 04/17/22 | 2D 3D TSV | |
US11191765 | 49 | 44 | HGNC:17270 | Heterocyclic compounds for the inhibition of PASK | BioEnergenix LLC | 04/17/22 | 2D 3D TSV |
US11192861 | 302 | 246 | HGNC:6371 | Human plasma kallikrein inhibitors | BioCryst Pharmaceuticals, Inc. | 04/17/22 | 2D 3D TSV |
US11192850 | 136 | 36 | HGNC:9642 HGNC:9644 HGNC:9658 | N-aryl oxamic acids | Purdue Research Foundation | 04/17/22 | 2D 3D TSV |
US11192893 | 6 | 6 | Pyrazoloquinazolinone antitumor agents | The Rockefeller University | 04/17/22 | 2D 3D TSV | |
US11192859 | 43 | 43 | Quinoline compounds as modulators of RAGE activity and uses thereof | TBA | 04/17/22 | 2D 3D TSV | |
US11192880 | 4 | 4 | Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) | 04/17/22 | 2D 3D TSV | |
US11192900 | 103 | 68 | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors | Nuvation Bio Inc. | 04/17/22 | 2D 3D TSV | |
US11179399 | 92 | 88 | HGNC:8974 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB | 04/10/22 | 2D 3D TSV |
US11186588 | 76 | 73 | HGNC:7794 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION | 04/10/22 | 2D 3D TSV |
US11180460 | 40 | 40 | HGNC:1133 | Amino pyrimidine derivatives | Novartis AG | 04/10/22 | 2D 3D TSV |
US11180482 | 48 | 46 | HGNC:6863 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors | ARIAD Pharmaceuticals, Inc. | 04/10/22 | 2D 3D TSV |
US11180502 | 14 | 14 | HGNC:10597 | Azaspiro[4.5]decane derivatives and use thereof | Purdue Pharma L.P. | 04/10/22 | 2D 3D TSV |
US11179370 | 8 | 8 | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers | Jenrin Discovery, LLC | 04/10/22 | 2D 3D TSV | |
US11186587 | 51 | 32 | HGNC:85 HGNC:84 | Compound as ACC inhibitor and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. | 04/10/22 | 2D 3D TSV |
US11180455 | 172 | 161 | HGNC:8156 | Compounds for the treatment of pain | TBA | 04/10/22 | 2D 3D TSV |
US11186580 | 8 | 4 | HGNC:8978 HGNC:8977 | Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor | Incyte Corporation | 04/10/22 | 2D 3D TSV |
US11186589 | 106 | 95 | HGNC:6853 | Cyanoindoline derivatives as NIK inhibitors | Janssen Pharmaceutica NV | 04/10/22 | 2D 3D TSV |
US11179397 | 147 | 145 | HGNC:9644 | Imidazopyrimidine derivatives | Gilead Sciences, Inc. | 04/10/22 | 2D 3D TSV |
US11179389 | 39 | 38 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | Merck Sharp & Dohme Corp. | 04/10/22 | 2D 3D TSV | |
US11180484 | 295 | 59 | HGNC:3530 HGNC:6371 HGNC:9475 HGNC:3529 HGNC:3535 HGNC:6357 | Pyrazole derivatives as plasma kallikrein inhibitors | KalVista Pharmaceuticals Limited | 04/10/22 | 2D 3D TSV |
US11186576 | 141 | 130 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | Aurigene Discovery Technologies Limited | 04/10/22 | 2D 3D TSV | |
US11186590 | 23 | 23 | HGNC:11331 | Somatostatin modulators and uses thereof | CRINETICS PHARMACEUTICALS, INC. | 04/10/22 | 2D 3D TSV |
US11186582 | 564 | 562 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors | Dart Neuroscience, (Cayman) LTD. | 04/10/22 | 2D 3D TSV | |
US11180494 | 197 | 183 | HGNC:6161 | Substituted amino acids as integrin inhibitors | Pliant Therapeutics, Inc. | 04/10/22 | 2D 3D TSV |
US11180471 | 516 | 254 | HGNC:6371 HGNC:3529 | Substituted oxopyridine derivatives | Bayer Pharma Aktiengesellschaft | 04/10/22 | 2D 3D TSV |
US11186578 | 6 | 6 | HGNC:1133 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | Shenzhen TargetRx, Inc. | 04/10/22 | 2D 3D TSV |
US11186579 | 36 | 35 | HGNC:6059 | Therapeutic heterocyclic compounds | Gilead Sciences, Inc. | 04/10/22 | 2D 3D TSV |
US11186577 | 549 | 212 | HGNC:8529 HGNC:897 HGNC:895 HGNC:896 | Vasopressin receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. | 04/10/22 | 2D 3D TSV |
US11180503 | 90 | 13 | HGNC:8783 HGNC:8775 HGNC:8774 HGNC:8776 HGNC:8778 | [1,2,4]Triazolo[4,3-A]pyrazin-6(5H)-one derivatives | ELI LILLY AND COMPANY | 04/10/22 | 2D 3D TSV |
US11185537 | 69 | 27 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | Novartis AG | 04/09/22 | 2D 3D TSV | |
US11185100 | 71 | 50 | HGNC:15661 | Methods for modulating taste receptors | MARS, INCORPORATED | 04/09/22 | 2D 3D TSV |
US11186566 | 99 | 64 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | Vertex Pharmaceuticals Incorporated | 04/09/22 | 2D 3D TSV | |
US11186554 | 166 | 164 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. | 04/09/22 | 2D 3D TSV | |
US11186544 | 90 | 45 | HGNC:3827 HGNC:3826 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | Bristol-Myers Squibb Company | 04/09/22 | 2D 3D TSV |
US11173161 | 73 | 73 | HGNC:19995 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | Takeda Pharmaceutical Company Limited | 04/03/22 | 2D 3D TSV |
US11173144 | 8 | 8 | HGNC:290 | Adrenergic receptor modulating compounds and methods of using the same | The Board of Trustees of the Leland Stanford Junior University | 04/03/22 | 2D 3D TSV |
US11174254 | 34 | 17 | HGNC:1133 HGNC:3236 | Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.; SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. | 04/03/22 | 2D 3D TSV |
US11174268 | 1277 | 333 | HGNC:10593 HGNC:10585 HGNC:10596 | Benzenesulfonamide compouds and their use as therapeutic agents | Xenon Pharmaceuticals Inc. | 04/03/22 | 2D 3D TSV |
US11174245 | 334 | 124 | Benzimidazole compounds and derivatives as EGFR inhibitors | Boehringer Ingelheim International GmbH | 04/03/22 | 2D 3D TSV | |
US11173162 | 856 | 187 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 04/03/22 | 2D 3D TSV |
US11173137 | 85 | 59 | HGNC:281 HGNC:4598 HGNC:4597 HGNC:4596 HGNC:4594 HGNC:5286 HGNC:4593 HGNC:1954 HGNC:1953 HGNC:1950 HGNC:1952 HGNC:4600 | Compositions and methods to modulate chloride ion channel activity | The Board of Trustees of the Leland Stanford Junior University | 04/03/22 | 2D 3D TSV |
US11174262 | 18 | 18 | Compounds, compositions and methods | Denali Therapeutics Inc. | 04/03/22 | 2D 3D TSV | |
US11174252 | 487 | 133 | HGNC:1780 HGNC:1771 HGNC:1778 HGNC:1777 HGNC:1722 HGNC:1774 HGNC:1773 HGNC:8977 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. | 04/03/22 | 2D 3D TSV |
US11174248 | 32 | 29 | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | Merck Sharp & Dohme Corp. | 04/03/22 | 2D 3D TSV | |
US11174244 | 634 | 303 | HGNC:4617 HGNC:3091 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BioSplice Therapeutics, Inc. | 04/03/22 | 2D 3D TSV |
US11174219 | 7 | 7 | Neprilysin inhibitors | Theravance Biopharma R&D IP, LLC | 04/03/22 | 2D 3D TSV | |
US11174250 | 205 | 126 | HGNC:12757 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. | 04/03/22 | 2D 3D TSV |
US11174232 | 95 | 89 | Substituted heterocyclyl derivatives as CDK inhibitors | Aurigene Discovery Technologies Limited | 04/03/22 | 2D 3D TSV | |
US11174264 | 21 | 19 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 04/03/22 | 2D 3D TSV | |
US10988505 | 14 | 5 | HGNC:16517 | Matriptase inhibitors and uses thereof | SOCIÉTÉ DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUÉE SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. | 03/30/22 | 2D 3D TSV |
US11136328 | 48 | 11 | HGNC:4586 HGNC:6251 HGNC:2625 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | Rugen Holdings (Cayman) Limited | 03/27/22 | 2D 3D TSV |
US11136312 | 309 | 71 | HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University | 03/27/22 | 2D 3D TSV |
US11166958 | 20 | 20 | HGNC:10478 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | Boehringer Ingelheim International GmbH | 03/27/22 | 2D 3D TSV |
US11168095 | 209 | 173 | HGNC:6857 | ASK1 inhibiting agents | BIOGEN MA INC. | 03/27/22 | 2D 3D TSV |
US11136340 | 91 | 13 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:11393 HGNC:11390 HGNC:9413 HGNC:12401 | Amino-triazolopyridine compounds and their use in treating cancer | AstraZeneca AB | 03/27/22 | 2D 3D TSV |
US11168102 | 253 | 135 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. | 03/27/22 | 2D 3D TSV | |
US11136315 | 35 | 35 | HGNC:6027 | CXCR2 antagonist | MEDSHINE DISCOVERY INC. | 03/27/22 | 2D 3D TSV |
US11168075 | 35 | 34 | HGNC:12805 | Compounds and their use for reducing uric acid levels | Acquist LLC | 03/27/22 | 2D 3D TSV |
US11168080 | 71 | 67 | Dynamin-1-like protein inhibitors | Mitobridge, Inc. | 03/27/22 | 2D 3D TSV | |
US11136333 | 19 | 10 | HGNC:76 | Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use | The Texas A&M University System | 03/27/22 | 2D 3D TSV |
US11168089 | 34 | 34 | HGNC:263 | Fused pyrimidine derivatives as A2A / A2B inhibitors | Incyte Corporation | 03/27/22 | 2D 3D TSV |
US11136320 | 25 | 25 | HGNC:3691 | Fused ring derivative used as FGFR4 inhibitor | JACOBIO PHARMACEUTICALS CO., LTD. | 03/27/22 | 2D 3D TSV |
US11136311 | 221 | 214 | HGNC:6853 | Heteroaromatic derivatives as NIK inhibitors | Janssen Pharmaceutica NV | 03/27/22 | 2D 3D TSV |
US11168069 | 12 | 6 | HGNC:12437 HGNC:4623 | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer | Oblique Therapeutics AB | 03/27/22 | 2D 3D TSV |
US11135210 | 8 | 8 | HGNC:17635 | Indane-amines as PD-L1 antagonists | ChemoCentryx, Inc. | 03/27/22 | 2D 3D TSV |
US11168083 | 82 | 66 | HGNC:6371 HGNC:9475 HGNC:3528 HGNC:3309 HGNC:3535 | Inhibitors of Plasma Kallikrein and uses thereof | Takeda Pharmaceutical Company Limited | 03/27/22 | 2D 3D TSV |
US11135207 | 42 | 42 | HGNC:13709 | Inhibitors of dihydroceramide desaturase for treating disease | Centaurus Therapeutics | 03/27/22 | 2D 3D TSV |
US11166942 | 56 | 55 | Inhibitors of integrated stress response pathway | PRAXIS BIOTECH LLC | 03/27/22 | 2D 3D TSV | |
US11136329 | 453 | 118 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | JAK inhibitors | VIMALAN BIOSCIENCES, INC. | 03/27/22 | 2D 3D TSV |
US11136327 | 77 | 77 | HGNC:3529 | Macrocycles as factor XIA inhibitors | Bristol-Myers Squibb Company | 03/27/22 | 2D 3D TSV |
US11136337 | 42 | 42 | HGNC:8127 | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | Boehringer Ingelheim International GmbH | 03/27/22 | 2D 3D TSV |
US11168088 | 178 | 56 | HGNC:1771 HGNC:1722 HGNC:1773 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | TBA | 03/27/22 | 2D 3D TSV |
US11168082 | 96 | 95 | HGNC:29079 | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 03/27/22 | 2D 3D TSV |
US11136325 | 20 | 7 | HGNC:6857 HGNC:6858 | Pyrrolopyrimidine and pyrrolopyridine derivatives | GALAPAGOS NV | 03/27/22 | 2D 3D TSV |
US11136326 | 289 | 96 | HGNC:6190 HGNC:7027 HGNC:12446 HGNC:8977 | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation | 03/27/22 | 2D 3D TSV |
US11136296 | 252 | 239 | HGNC:9600 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft | 03/27/22 | 2D 3D TSV |
US11136324 | 38 | 38 | HGNC:6857 | Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors | Jiangsu Hansoh Pharmaceutical Group Co., Ltd.; Shanghai Hansoh Biomedical Co., Ltd. | 03/27/22 | 2D 3D TSV |
US11168090 | 232 | 115 | HGNC:9967 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | Array BioPharma Inc. | 03/27/22 | 2D 3D TSV |
US11168070 | 125 | 125 | HGNC:2348 | Therapeutic compounds and uses thereof | GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. | 03/27/22 | 2D 3D TSV |
US11168093 | 183 | 135 | HGNC:10020 | Thienopyridine inhibitors of RIPK2 | Celgene Corporation | 03/27/22 | 2D 3D TSV |
US11136336 | 22 | 22 | HGNC:497 | Thienopyrimidones | Boehringer Ingelheim International GmbH | 03/27/22 | 2D 3D TSV |
US11161839 | 234 | 186 | 2-quinolone derived inhibitors of BCL6 | The Institute of Cancer Research: Royal Cancer Hospital; Cancer Research Technology Limited | 03/20/22 | 2D 3D TSV | |
US11161835 | 15 | 15 | HGNC:12805 | Compounds and their use for reducing uric acid levels | Acquist LLC | 03/20/22 | 2D 3D TSV |
US11161844 | 99 | 37 | HGNC:18618 | Cyclic substituted imidazo[4,5-c]quinoline derivatives | PFIZER INC. | 03/20/22 | 2D 3D TSV |
US11161850 | 128 | 113 | HGNC:263 | Fused pyrazine derivatives as A2A / A2B inhibitors | Incyte Corporation | 03/20/22 | 2D 3D TSV |
US11161838 | 26 | 13 | HGNC:8978 HGNC:8977 | Heterocyclic derivatives as PI3K inhibitors | Incyte Corporation | 03/20/22 | 2D 3D TSV |
US11161815 | 65 | 33 | HGNC:12437 HGNC:4623 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | Oblique Therapeutics AB | 03/20/22 | 2D 3D TSV |
US11161854 | 111 | 77 | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | Merck Sharp & Dohme Corp. | 03/20/22 | 2D 3D TSV | |
US11161849 | 6 | 6 | HGNC:497 | Inhibiting the transient receptor potential al ion channel | Eli Lilly and Company | 03/20/22 | 2D 3D TSV |
US11161852 | 44 | 44 | HGNC:13386 | Inhibitors of NEK7 kinase | HALIA THERAPEUTICS, INC. | 03/20/22 | 2D 3D TSV |
US11161848 | 544 | 530 | HGNC:12607 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA Therapeutics, Inc. | 03/20/22 | 2D 3D TSV |
US11160797 | 364 | 48 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG | 03/20/22 | 2D 3D TSV | |
US11161864 | 245 | 76 | Sting agonists | VENENUM BIODESIGN, LLC | 03/20/22 | 2D 3D TSV | |
US11161855 | 196 | 97 | Tricyclic fused thiophene derivatives as JAK inhibitors | Incyte Corporation; Incyte Holdings Corporation | 03/20/22 | 2D 3D TSV | |
US11155546 | 138 | 71 | HGNC:1133 HGNC:3236 | 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.; YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. | 03/13/22 | 2D 3D TSV |
US11154544 | 4 | 4 | HGNC:10597 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RaQualia Pharma Inc. | 03/13/22 | 2D 3D TSV |
US11149022 | 66 | 66 | HGNC:1953 | Antagonists of the muscarinic acetylcholine receptor M4 | Vanderbilt University | 03/13/22 | 2D 3D TSV |
US11149056 | 26 | 13 | HGNC:4586 | C7 substituted oxysterols and methods of use thereof | SAGE THERAPEUTICS, INC. | 03/13/22 | 2D 3D TSV |
US11149013 | 2 | 2 | HGNC:17989 | Crystal form of urate transporter 1 inhibitor and preparation method and use thereof | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD. | 03/13/22 | 2D 3D TSV |
US11155532 | 130 | 129 | HGNC:29079 | Cyclopropylamines as LSD1 inhibitors | Incyte Corporation | 03/13/22 | 2D 3D TSV |
US11155558 | 31 | 30 | HGNC:8784 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG | 03/13/22 | 2D 3D TSV |
US11149009 | 37 | 35 | HGNC:1338 | Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor | InflaRx GmbH | 03/13/22 | 2D 3D TSV |
US11149040 | 75 | 38 | HGNC:339 | Fused triazole agonists of the APJ receptor | Amgen Inc. | 03/13/22 | 2D 3D TSV |
US11155544 | 58 | 57 | HGNC:1133 | Heterocycle comprising tyrosine kinase inhibitors | Principia Biopharma Inc. | 03/13/22 | 2D 3D TSV |
US11149020 | 100 | 46 | HGNC:2452 HGNC:6876 | MAP kinase modulators and uses thereof | The Trustees of Columbia University in the City of New York; Northwestern University | 03/13/22 | 2D 3D TSV |
US11149054 | 314 | 157 | HGNC:4586 | Oxysterols and methods of use thereof | SAGE THERAPEUTICS, INC. | 03/13/22 | 2D 3D TSV |
US11149292 | 1 | 1 | HGNC:3165 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | Arena Pharmaceuticals, Inc. | 03/13/22 | 2D 3D TSV |
US11149037 | 64 | 37 | HGNC:3553 HGNC:17038 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S | 03/13/22 | 2D 3D TSV |
US11155557 | 308 | 140 | HGNC:6190 HGNC:6192 | Pyrazolopyrimidine compounds and methods of use thereof | Genentech, Inc. | 03/13/22 | 2D 3D TSV |
US11155556 | 68 | 17 | HGNC:11393 HGNC:11390 HGNC:8973 HGNC:8975 HGNC:8977 HGNC:8976 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. | 03/13/22 | 2D 3D TSV |
US11149031 | 768 | 251 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | Sanofi | 03/13/22 | 2D 3D TSV | |
US11149018 | 289 | 272 | HGNC:9600 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft | 03/13/22 | 2D 3D TSV |
US11149049 | 50 | 12 | Substituted nucleosides, nucleotides and analogs thereof | JANSSEN BIOPHARMA, INC. | 03/13/22 | 2D 3D TSV | |
US11149023 | 140 | 70 | HGNC:897 HGNC:895 | Substituted triazole derivatives and uses thereof | Bayer Pharma Aktiengesellschaft | 03/13/22 | 2D 3D TSV |
US11149067 | 112 | 33 | HGNC:3309 HGNC:2521 | Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors | UNIVERSITÄT DUISBURG-ESSEN | 03/13/22 | 2D 3D TSV |
US11149066 | 15 | 15 | Thrombospondin 1-binding peptide | DAIICHI SANKYO COMPANY, LIMITED; PEPTIDREAM INC. | 03/13/22 | 2D 3D TSV | |
US11147816 | 9 | 8 | HGNC:6840 HGNC:6842 | Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition | GENUV Inc. | 03/12/22 | 2D 3D TSV |
US11147877 | 20 | 17 | Compositions and methods for treating CNS disorders | Sage Therapeutics, Inc. | 03/12/22 | 2D 3D TSV | |
US11149006 | 8 | 2 | HGNC:11526 HGNC:11527 HGNC:11528 | Compounds as neurokinin-1 receptor antagonists and uses thereof | XWPHARMA LTD. | 03/12/22 | 2D 3D TSV |
US11147820 | 10 | 5 | HGNC:3023 HGNC:3024 HGNC:3020 | Methods for treating GI tract disorders | NEUROGASTRX, INC. | 03/12/22 | 2D 3D TSV |
US11147801 | 29 | 29 | HGNC:2867 | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | Aurigene Discovery Technologies Limited | 03/12/22 | 2D 3D TSV |
US11130745 | 268 | 215 | HGNC:2867 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGELLSCHAFT; BAYER PHARMA AKTIEGELLSCHAFT; THE BROAD INSTITUTE INC.; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE GENERAL HOSPITAL CORPORATION | 03/08/22 | 2D 3D TSV |
US11130759 | 752 | 715 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCE, INC. | 03/08/22 | 2D 3D TSV | |
US11130767 | 38 | 38 | HGNC:8977 | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors | Incyte Corporation | 03/08/22 | 2D 3D TSV |
US11130750 | 27 | 15 | HGNC:2637 HGNC:2625 | Calcium channel inhibitors | CAVION, INC. | 03/08/22 | 2D 3D TSV |
US11130748 | 79 | 78 | Compounds | MISSION THERAPEUTICS LIMITED | 03/08/22 | 2D 3D TSV | |
US11129827 | 120 | 60 | HGNC:3553 HGNC:17038 | Dual MAGL and FAAH inhibitors | Abide Therapeutics, Inc. | 03/08/22 | 2D 3D TSV |
US11129828 | 68 | 66 | HGNC:2671 | Pyridazinone compounds and their use as DAAO inhibitors | Takeda Pharmaceutical Company Limited | 03/08/22 | 2D 3D TSV |
US11130769 | 312 | 308 | HGNC:6943 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | Prelude Therapeutics, Incorporated | 03/08/22 | 2D 3D TSV |
US11130740 | 19 | 17 | HGNC:17635 | Substituted 2,3-dihydro-1H-indene analogs and methods using same | Arbutus Biopharma Corporation | 03/08/22 | 2D 3D TSV |
US11130754 | 97 | 95 | HGNC:10020 | Substituted benzamides as RIPK2 inhibitors | Boehringer Ingelheim International GmbH | 03/08/22 | 2D 3D TSV |
US11142525 | 184 | 179 | HGNC:6863 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. | 03/04/22 | 2D 3D TSV |
US11141403 | 63 | 61 | Benzimidazoles and indoles as taro inhibitors | MERCK SHARP & DOHME CORP | 03/04/22 | 2D 3D TSV | |
US11142505 | 71 | 58 | HGNC:933 | Compositions for APP-selective BACE inhibition and uses therefor | The Regents of the University of California | 03/04/22 | 2D 3D TSV |
US11142531 | 15 | 13 | HGNC:85 HGNC:84 | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. | 03/04/22 | 2D 3D TSV |
US11142527 | 99 | 99 | Dihydropyrimidine compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. | 03/04/22 | 2D 3D TSV | |
US11142535 | 35 | 21 | HGNC:4852 HGNC:11491 HGNC:14064 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor | Hangzhou Innogate Pharma Co., Ltd. | 03/04/22 | 2D 3D TSV |
US11142507 | 105 | 35 | HGNC:1780 HGNC:1771 HGNC:1778 | Inhibitors of cyclin-dependent kinases | Dana-Farber Cancer Institute, Inc. | 03/04/22 | 2D 3D TSV |
US11142520 | 74 | 37 | HGNC:6541 HGNC:6535 | LDHA activity inhibitors | ARCTIC PHARMA AS | 03/04/22 | 2D 3D TSV |
US11141411 | 3 | 3 | HGNC:9236 | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone | Poxel SA | 03/04/22 | 2D 3D TSV |
US11141410 | 99 | 99 | Oxazolidinones as taro inhibitors | MERCK SHARP & DOHME CORP | 03/04/22 | 2D 3D TSV | |
US11142526 | 224 | 187 | HGNC:17038 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S | 03/04/22 | 2D 3D TSV |
US11142524 | 61 | 51 | HGNC:3356 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | STINGRAY THERAPEUTICS, INC. | 03/04/22 | 2D 3D TSV |
US11117865 | 99 | 8 | HGNC:2348 | Inhibitors of bromodomain-containing protein 4 (BRD4) | Board of Regents, The University Of Texas System | 03/02/22 | 2D 3D TSV |
US11124523 | 88 | 34 | HGNC:6251 HGNC:2637 HGNC:8156 HGNC:2625 HGNC:2623 HGNC:2621 | 2,6-dioxaspiro [4,5] decane derivatives and preparation method therefor and pharmaceutical applications thereof | TBA | 02/26/22 | 2D 3D TSV |
US11124510 | 50 | 24 | HGNC:15631 HGNC:15632 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION | 02/26/22 | 2D 3D TSV |
US11117874 | 37 | 37 | HGNC:2528 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB | 02/26/22 | 2D 3D TSV |
US11116764 | 6 | 3 | HGNC:5301 | Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonist | Suven Life Sciences Limited | 02/26/22 | 2D 3D TSV |
US11117900 | 587 | 546 | HGNC:882 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED | 02/26/22 | 2D 3D TSV |
US11124500 | 76 | 38 | Disubstituted pyrazole compounds | Eli Lilly and Company | 02/26/22 | 2D 3D TSV | |
US11124511 | 34 | 33 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 02/26/22 | 2D 3D TSV | |
US11124496 | 7 | 7 | HGNC:6857 | Imidazolidine compounds | Eli Lilly and Company | 02/26/22 | 2D 3D TSV |
US11124537 | 103 | 101 | HGNC:7978 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. | 02/26/22 | 2D 3D TSV |
US11117891 | 4 | 4 | HGNC:6857 | Isoquinolin and naphthydrin compounds | Eli Lilly and Company | 02/26/22 | 2D 3D TSV |
US11124504 | 383 | 184 | HGNC:8154 HGNC:8156 | Kappa opioid receptor antagonists and products and methods related thereto | THE SCRIPPS RESEARCH INSTITUTE; BLACKTHORN THERAPEUTICS, INC. | 02/26/22 | 2D 3D TSV |
US11124518 | 28 | 28 | HGNC:12761 | L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs | Recurium IP Holdings, LLC | 02/26/22 | 2D 3D TSV |
US11116757 | 690 | 635 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER; ST. JUDE CHILDREN''S RESEARCH HOSPITAL | 02/26/22 | 2D 3D TSV | |
US11124538 | 66 | 62 | Neuroactive steroids, compositions, and uses thereof | Sage Therapeutics, Inc. | 02/26/22 | 2D 3D TSV | |
US11117861 | 270 | 127 | HGNC:3827 HGNC:3826 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | Bristol-Myers Squibb Company | 02/26/22 | 2D 3D TSV |
US11117898 | 21 | 7 | HGNC:2637 HGNC:2625 | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 02/26/22 | 2D 3D TSV |
US11117892 | 40 | 39 | HGNC:3091 | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases | TBA | 02/26/22 | 2D 3D TSV |
US11117902 | 44 | 22 | HGNC:3467 | Selective estrogen receptor degraders | Eli Lilly and Company | 02/26/22 | 2D 3D TSV |
US11124495 | 34 | 32 | Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection | Hoffmann-La Roche, Inc. | 02/26/22 | 2D 3D TSV | |
US11124509 | 50 | 50 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. | 02/26/22 | 2D 3D TSV | |
US11111253 | 170 | 117 | HGNC:11364 HGNC:11362 | 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity | University of Pittsburgh—Of the Commonwealth System of Higher Education | 02/22/22 | 2D 3D TSV |
US11111270 | 105 | 39 | HGNC:13702 | Inhibitor of apoptosis protein (IAP) antagonists | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE | 02/22/22 | 2D 3D TSV |
US11111247 | 384 | 81 | HGNC:3690 HGNC:3689 HGNC:3688 | Pyrazolopyrimidine compounds and uses thereof | Incyte Corporation | 02/22/22 | 2D 3D TSV |
US11111252 | 32 | 12 | HGNC:3763 HGNC:2861 HGNC:6307 HGNC:8804 HGNC:3236 | Pyrimidine compounds and pyrimido indole compounds and methods of use | Duquesne University of The Holy Spirit | 02/22/22 | 2D 3D TSV |
US11124486 | 1232 | 1227 | HGNC:8537 | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. | 02/21/22 | 2D 3D TSV |
US11111233 | 136 | 64 | HGNC:3236 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | Shenzhen TargetRx, Inc. | 02/21/22 | 2D 3D TSV |
US11124494 | 86 | 71 | HGNC:3827 HGNC:3826 | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | Bristol-Myers Squibb Company | 02/21/22 | 2D 3D TSV |
US11124490 | 26 | 23 | HGNC:10548 | Autotaxin inhibitors | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION; UNIVERSITY OF MEMPHIS | 02/21/22 | 2D 3D TSV |
US11111237 | 256 | 250 | HGNC:10894 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. | 02/21/22 | 2D 3D TSV |
US11111235 | 232 | 164 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. | 02/21/22 | 2D 3D TSV | |
US11124489 | 76 | 53 | HGNC:16629 HGNC:16626 | EPAC antagonists | Board of Regents, the University of Texas System | 02/21/22 | 2D 3D TSV |
US11110088 | 111 | 17 | HGNC:3432 HGNC:3430 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:11719 HGNC:12434 HGNC:3236 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | Acerta Pharma B.V. | 02/21/22 | 2D 3D TSV |
US11123311 | 64 | 62 | HGNC:3402 | Methods of treating mental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 02/21/22 | 2D 3D TSV |
US11110095 | 106 | 43 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrimidine compounds as JAK kinase inhibitors | Theravance Biopharma R&D IP, LLC | 02/21/22 | 2D 3D TSV |
US11111242 | 611 | 315 | HGNC:6193 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | Pfizer Inc. | 02/21/22 | 2D 3D TSV |
US11111240 | 29 | 27 | Sultam compound and application method thereof | Chai Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd.; Centaurus Biopharma Co., Ltd. | 02/21/22 | 2D 3D TSV | |
US11104680 | 85 | 27 | HGNC:8775 HGNC:8774 HGNC:8776 | 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors | H. Lundbeck A/S | 02/13/22 | 2D 3D TSV |
US11104664 | 48 | 47 | 4,5,6-trisubstituted indazole derivatives, and preparation method and pharmaceutical use thereof | TBA | 02/13/22 | 2D 3D TSV | |
US11053244 | 3210 | 843 | HGNC:15633 HGNC:15631 HGNC:15632 | 4-azaindole compounds | Bristol-Myers Squibb Company | 02/13/22 | 2D 3D TSV |
US11104670 | 13 | 13 | HGNC:4586 | 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament | Boehringer Ingelheim International GmbH | 02/13/22 | 2D 3D TSV |
USRE48711 | 264 | 262 | HGNC:6857 | Apoptosis signal-regulating kinase inhibitors | Gilead Sciences, Inc. | 02/13/22 | 2D 3D TSV |
US11053238 | 60 | 15 | HGNC:1780 HGNC:1771 HGNC:1778 | Benzimidazole derivatives, preparation methods and uses thereof | BETTA PHARMACEUTICALS CO., LTD. | 02/13/22 | 2D 3D TSV |
US11104690 | 200 | 199 | HGNC:16940 | Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | Merck Sharp & Dohme Corp. | 02/13/22 | 2D 3D TSV |
US11104668 | 20 | 20 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | Hoffmann-La Roche Inc.; Chugai Pharmaceutical Co. | 02/13/22 | 2D 3D TSV |
US11053243 | 50 | 50 | Inhibitors of hepatitis C virus replication | Merck Sharp & Dohme Corp. | 02/13/22 | 2D 3D TSV | |
US11103510 | 26 | 26 | JAK1 pathway inhibitors for the treatment of cytokine-related disorders | Incyte Corporation | 02/13/22 | 2D 3D TSV | |
US11053226 | 703 | 379 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. | 02/13/22 | 2D 3D TSV | |
US11053253 | 229 | 223 | HGNC:2771 | Macrocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. | 02/13/22 | 2D 3D TSV |
US11104675 | 29 | 21 | PTPN11 inhibitors | NAVIRE PHARMA, INC. | 02/13/22 | 2D 3D TSV | |
US11104676 | 1973 | 188 | HGNC:7027 HGNC:12446 HGNC:7029 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | Array BioPharma Inc. | 02/13/22 | 2D 3D TSV |
US11104665 | 14 | 14 | HGNC:3357 | Pyridazines | Boehringer Ingelheim International GmbH | 02/13/22 | 2D 3D TSV |
US11053225 | 426 | 138 | HGNC:7027 HGNC:12446 | Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating Tyro 3 related disease comprising same as active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY | 02/13/22 | 2D 3D TSV |
US11053247 | 22 | 8 | HGNC:6371 HGNC:3529 | Pyrimidinones as factor XIA inhibitors | Bristol-Myers Squibb Company | 02/13/22 | 2D 3D TSV |
US11053250 | 10 | 10 | HGNC:17967 | Pyrrolo[1,2-b]pyridazine derivatives | Gilead Sciences, Inc. | 02/13/22 | 2D 3D TSV |
US11104682 | 6 | 2 | HGNC:7027 HGNC:12446 | Salts of TAM inhibitors | Incyte Corporation | 02/13/22 | 2D 3D TSV |
US11053219 | 146 | 106 | HGNC:6190 HGNC:6192 HGNC:12440 | Substituted pyridines as TYK2 inhibitors | Esker Therapeutics, Inc. | 02/13/22 | 2D 3D TSV |
US11053246 | 699 | 233 | HGNC:3690 HGNC:3689 HGNC:3688 | Substituted tricyclic compounds as FGFR inhibitors | Incyte Corporation; Incyte Holdings Corporation | 02/13/22 | 2D 3D TSV |
US11053241 | 101 | 96 | HGNC:12440 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 02/13/22 | 2D 3D TSV |
US11053242 | 166 | 156 | HGNC:10935 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | Neurocrine Biosciences, Inc. | 02/13/22 | 2D 3D TSV |
US11098029 | 75 | 71 | HGNC:4849 | 5-alkyl pyrrolidine orexin receptor agonists | Merck Sharp & Dohme Corp. | 02/07/22 | 2D 3D TSV |
US11098048 | 68 | 64 | HGNC:10548 | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | Hoffmann-La Roche Inc. | 02/07/22 | 2D 3D TSV |
US11098058 | 163 | 149 | Bicyclic ketone compounds and methods of use thereof | Genentech, Inc. | 02/07/22 | 2D 3D TSV | |
US11098063 | 264 | 113 | HGNC:6283 HGNC:6278 | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft | 02/07/22 | 2D 3D TSV |
US11098045 | 462 | 116 | HGNC:6834 HGNC:550 HGNC:6666 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | Pharmaxis Ltd. | 02/07/22 | 2D 3D TSV |
US11098041 | 305 | 179 | HGNC:1133 HGNC:6524 | Heteroaryl compounds as BTK inhibitors and uses thereof | Merck Patent GmbH | 02/07/22 | 2D 3D TSV |
US11098044 | 271 | 103 | HGNC:18618 HGNC:76 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. | 02/07/22 | 2D 3D TSV |
US11098031 | 140 | 126 | HGNC:9829 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. | 02/07/22 | 2D 3D TSV |
US11098061 | 218 | 126 | HGNC:6887 | MK2 inhibitors and uses thereof | Celgene CAR LLC | 02/07/22 | 2D 3D TSV |
US11098060 | 76 | 32 | HGNC:8031 | Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; CENTAURUS BIOPHARMA CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. | 02/07/22 | 2D 3D TSV |
US11098046 | 40 | 40 | HGNC:8031 | Macrocyclic compounds as TRK kinase inhibitors and uses thereof | ANGEX PHARMACEUTICAL, INC. | 02/07/22 | 2D 3D TSV |
US11098059 | 60 | 26 | HGNC:29652 | PRMT5 inhibitors | Merck Sharp & Dohme Corp. | 02/07/22 | 2D 3D TSV |
US11098034 | 4 | 4 | HGNC:9602 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 02/07/22 | 2D 3D TSV |
US11053198 | 117 | 116 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED | 02/06/22 | 2D 3D TSV | |
US11052087 | 10 | 10 | Anti-HIV compounds | Gilead Sciences, Inc. | 02/06/22 | 2D 3D TSV | |
US11052093 | 334 | 184 | HGNC:3527 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. | 02/06/22 | 2D 3D TSV |
US11052091 | 21 | 21 | HGNC:9617 | BRK inhibitory compound | ONO PHARMACEUTICAL CO., LTD. | 02/06/22 | 2D 3D TSV |
US11053197 | 200 | 165 | HGNC:1133 | Carbazole derivatives | Bristol-Myers Squibb Company | 02/06/22 | 2D 3D TSV |
US11096924 | 330 | 49 | HGNC:16490 HGNC:18648 HGNC:3590 HGNC:3009 HGNC:14892 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | Trustees of Tufts College | 02/06/22 | 2D 3D TSV |
US11053216 | 207 | 36 | HGNC:171 HGNC:1076 HGNC:172 HGNC:175 | Compounds and methods of use | Medivation Technologies LLC | 02/06/22 | 2D 3D TSV |
US11096942 | 94 | 47 | HGNC:3236 | Heterocyclic compounds and uses thereof | Celgene CAR LLC | 02/06/22 | 2D 3D TSV |
US11053215 | 510 | 168 | HGNC:19310 HGNC:8987 | Heterocyclic compounds useful as Pim kinase inhibitors | Incyte Corporation | 02/06/22 | 2D 3D TSV |
US11053207 | 20 | 18 | HGNC:6059 | Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences | 02/06/22 | 2D 3D TSV |
US11053213 | 252 | 252 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED | 02/06/22 | 2D 3D TSV | |
US11096930 | 36 | 19 | HGNC:11708 HGNC:6059 | Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase | Merck Sharp & Dohme Corp.; IOmet Pharma Ltd. | 02/06/22 | 2D 3D TSV |
US11053196 | 26 | 26 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc.; Kathalieke Universiteif Leuven | 02/06/22 | 2D 3D TSV | |
US11059821 | 196 | 96 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins | Incyte Corporation | 02/02/22 | 2D 3D TSV | |
US11059825 | 184 | 129 | HGNC:23692 | CXCR7 antagonists | ChemoCentryx, Inc. | 02/02/22 | 2D 3D TSV |
US11059827 | 25 | 25 | HGNC:8031 | Compounds and compositions useful for treating disorders related to NTRK | Blueprint Medicines Corporation | 02/02/22 | 2D 3D TSV |
US11059830 | 16 | 10 | HGNC:3711 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. | 02/02/22 | 2D 3D TSV |
US11059858 | 61 | 60 | Difluoroketamide derivatives as HtrA1 inhibitors | Hoffmann-La Roche Inc. | 02/02/22 | 2D 3D TSV | |
US11059828 | 739 | 376 | HGNC:4849 HGNC:4848 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | Janssen Pharmaceutica NV | 02/02/22 | 2D 3D TSV |
US11059822 | 25 | 25 | HGNC:17038 | MAGL inhibitors | H. LUNDBECK A/S | 02/02/22 | 2D 3D TSV |
US11059834 | 25 | 24 | Macrocyclic immunomodulators | ChemoCentryx, Inc. | 02/02/22 | 2D 3D TSV | |
US11059842 | 37 | 30 | Monosaccharide amine and 3-nitro-2-phenyl-2H-chromene based inhibitors of glucose kinases | University of South Carolina | 02/02/22 | 2D 3D TSV | |
US11059823 | 60 | 15 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Small molecule inhibitors of the JAK family of kinases | Janssen Pharmaceutica NV | 02/02/22 | 2D 3D TSV |
US11059824 | 30 | 30 | HGNC:15631 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. | 02/02/22 | 2D 3D TSV |
US11059818 | 111 | 56 | HGNC:7218 | Triazolopyridine inhibitors of myeloperoxidase | Bristol-Myers Squibb Company | 02/02/22 | 2D 3D TSV |
US11091488 | 78 | 78 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED | 01/30/22 | 2D 3D TSV | |
US11091474 | 4 | 4 | HGNC:11138 | Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL | 01/30/22 | 2D 3D TSV |
US11091445 | 12 | 6 | HGNC:7463 HGNC:7464 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. | 01/30/22 | 2D 3D TSV |
US11091444 | 12 | 7 | HGNC:620 | Hydantoins that modulate BACE-mediated app processing | BUCK INSTITUTE FOR RESEARCH ON AGING | 01/30/22 | 2D 3D TSV |
US11091485 | 80 | 40 | HGNC:1773 | Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. | 01/30/22 | 2D 3D TSV |
US11091471 | 202 | 200 | HGNC:6141 HGNC:4075 | Isoxazolyl ether derivatives as GABAA α5 PAM | Hoffmann-La Roche Inc. | 01/30/22 | 2D 3D TSV |
US11091482 | 63 | 63 | HGNC:7967 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. | 01/30/22 | 2D 3D TSV |
US11091472 | 200 | 113 | HGNC:8978 HGNC:8984 HGNC:8973 HGNC:8972 HGNC:8983 HGNC:8975 | PI-kinase inhibitors with anti-infective activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 01/30/22 | 2D 3D TSV |
US11091476 | 215 | 46 | HGNC:1771 | Protein kinase inhibitors, preparation method and medical use thereof | Gan & Lee Pharmaceuticals | 01/30/22 | 2D 3D TSV |
US11091451 | 142 | 70 | HGNC:10850 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. | 01/30/22 | 2D 3D TSV |
US11091495 | 233 | 218 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | MIRATI THERAPEUTICS, INC. | 01/30/22 | 2D 3D TSV | |
US11091484 | 546 | 270 | Tricyclic heterocycles as BET protein inhibitors | Incyte Corporation | 01/30/22 | 2D 3D TSV | |
US11084810 | 40 | 20 | HGNC:2160 HGNC:2159 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | Centrexion Therapeutics Corporation | 01/24/22 | 2D 3D TSV |
US11084821 | 27 | 27 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED | 01/24/22 | 2D 3D TSV | |
US11084809 | 188 | 92 | HGNC:6371 HGNC:6357 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KalVista Pharmaceuticals Limited | 01/24/22 | 2D 3D TSV |
US11084808 | 111 | 107 | HGNC:3529 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 01/24/22 | 2D 3D TSV |
US11084824 | 53 | 51 | HGNC:1133 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY | 01/24/22 | 2D 3D TSV |
US11084822 | 26 | 26 | HGNC:6190 | Salts and processes of preparing a PI3K inhibitor | Incyte Corporation | 01/24/22 | 2D 3D TSV |
US11084823 | 100 | 51 | HGNC:1133 HGNC:6193 | Substituted pyrrolo[2,1-f][1,2,4]triazines as kinase inhibitors | Daewoong Pharmaceutical Co., Ltd. | 01/24/22 | 2D 3D TSV |
US11084798 | 749 | 713 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. | 01/23/22 | 2D 3D TSV | |
US11084800 | 569 | 565 | HGNC:2771 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. | 01/23/22 | 2D 3D TSV |
US11059811 | 43 | 33 | Benzofuran derivative, preparation method thereof and use thereof in medicine | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 01/23/22 | 2D 3D TSV | |
US11059766 | 16 | 6 | HGNC:4597 | Ethynyl derivatives | Hoffmann-La Roche Inc. | 01/23/22 | 2D 3D TSV |
US11059794 | 142 | 70 | HGNC:1373 HGNC:10548 | Heterocyclic compounds useful as dual ATX/CA inhibitors | Hoffmann-La Roche Inc. | 01/23/22 | 2D 3D TSV |
US11059792 | 28 | 28 | HGNC:7873 | Imidazolyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. | 01/23/22 | 2D 3D TSV |
US11058688 | 252 | 122 | Imidazopiperazine inhibitors of transcription activating proteins | Board of Regents, The University of Texas System | 01/23/22 | 2D 3D TSV | |
US11083720 | 9 | 9 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | Regents of the University of Colorado, a body corporate; Colorado Research Partners. LLC | 01/23/22 | 2D 3D TSV | |
US11084793 | 121 | 118 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research, Inc. | 01/23/22 | 2D 3D TSV |
US11059789 | 98 | 21 | HGNC:6190 HGNC:9380 HGNC:6192 HGNC:9393 HGNC:6193 HGNC:10251 HGNC:11892 HGNC:12440 HGNC:10252 HGNC:391 HGNC:5960 HGNC:9399 HGNC:9401 | Isoquinoline-steroid conjugates and uses thereof | Aerie Pharmaceuticals, Inc. | 01/23/22 | 2D 3D TSV |
US11059801 | 108 | 84 | HGNC:2717 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. | 01/23/22 | 2D 3D TSV |
US11059784 | 85 | 31 | HGNC:3167 HGNC:3165 | Oxime ether compounds | Bristol-Myers Squibb Company | 01/23/22 | 2D 3D TSV |
US11058676 | 21 | 21 | HGNC:6666 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. | 01/23/22 | 2D 3D TSV |
US11084784 | 7 | 7 | ROR-gamma modulators and uses thereof | PIRAMAL ENTERPRISES LIMITED | 01/23/22 | 2D 3D TSV | |
US11058696 | 33 | 12 | HGNC:3167 | Substituted bicyclic compounds | Bristol-Myers Squibb Company | 01/23/22 | 2D 3D TSV |
US11059809 | 7 | 7 | Substituted cyanopyrrolidines with activity as DUB inhibitors | MISSION THERAPEUTICS LIMITED | 01/23/22 | 2D 3D TSV | |
US11078197 | 160 | 158 | HGNC:10252 | 5-membered and bicyclic heterocyclic amides as inhibitors of rock | Bristol-Myers Squibb Company | 01/16/22 | 2D 3D TSV |
US11077113 | 17 | 17 | HGNC:8974 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB | 01/16/22 | 2D 3D TSV |
US11078206 | 26 | 14 | HGNC:1133 HGNC:6193 | Amino-fluoropiperidine derivatives as kinase inhibitor | Daewoong Pharmaceutical Co., Ltd. | 01/16/22 | 2D 3D TSV |
US11078192 | 69 | 69 | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | TBA | 01/16/22 | 2D 3D TSV | |
US11078188 | 39 | 39 | HGNC:13575 | Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 01/16/22 | 2D 3D TSV |
US11078228 | 202 | 201 | HGNC:8021 | Ectonucleotidase inhibitors and methods of use thereof | Calithera Biosciences, Inc. | 01/16/22 | 2D 3D TSV |
US11078182 | 32 | 32 | Heteroaromatic compounds as Vanin inhibitors | Boehringer Ingelheim International GmbH | 01/16/22 | 2D 3D TSV | |
US11078196 | 13 | 13 | HGNC:11138 | Heteroaryl amides as inhibitors of protein aggregation | UCB Biophama SRL | 01/16/22 | 2D 3D TSV |
US11078204 | 102 | 51 | HGNC:8978 HGNC:8977 | Heterocyclic derivatives as PI3K inhibitors | Incyte Corporation | 01/16/22 | 2D 3D TSV |
US11078214 | 36 | 17 | HGNC:2861 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | Duquesne University of The Holy Spirit | 01/16/22 | 2D 3D TSV |
US11078199 | 159 | 155 | HGNC:3688 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. | 01/16/22 | 2D 3D TSV |
US11078186 | 177 | 155 | ROR γ modulators | Bristol-Myers Squibb Company | 01/16/22 | 2D 3D TSV | |
US11077128 | 6 | 3 | Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure | Yeda Research and Development Co. Ltd. | 01/16/22 | 2D 3D TSV | |
US11078205 | 42 | 42 | HGNC:10894 | Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) | Prelude Therapeutics, Incorporated | 01/16/22 | 2D 3D TSV |
US11078201 | 837 | 819 | HGNC:6863 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. | 01/16/22 | 2D 3D TSV |
US11077100 | 354 | 354 | HGNC:8537 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | RaQualia Pharma Inc.; Asahi Kasei Pharma Corporation | 01/16/22 | 2D 3D TSV |
US11077107 | 61 | 60 | Triazolopyrazine | TBA | 01/16/22 | 2D 3D TSV | |
US11077111 | 8 | 2 | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals | Bayer Animal Health GmbH | 01/16/22 | 2D 3D TSV | |
US20200361871 | 233 | 229 | HGNC:21625 | COMPOUNDS | Enterprise Therapeutics Ltd | 01/13/22 | 2D 3D TSV |
US11124497 | 463 | 179 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. | 01/13/22 | 2D 3D TSV | |
US11072585 | 122 | 116 | HGNC:6666 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. | 01/09/22 | 2D 3D TSV |
US11071729 | 29 | 29 | HGNC:4594 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones | Addex Pharmaceuticals S.A.; Janssen Pharmaceuticals, Inc. | 01/07/22 | 2D 3D TSV |
US11071788 | 26 | 21 | HGNC:6388 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT | 01/07/22 | 2D 3D TSV |
US11071721 | 107 | 101 | Bicyclic amide compounds and methods of use thereof | Genentech, Inc. | 01/07/22 | 2D 3D TSV | |
US11072617 | 225 | 223 | Bicyclic sulfones and sulfoxides and methods of use thereof | Genentech, Inc. | 01/07/22 | 2D 3D TSV | |
US11072611 | 367 | 215 | HGNC:3357 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV | 01/07/22 | 2D 3D TSV |
US11072607 | 46 | 41 | Inhibitors of RIP1 kinase and methods of use thereof | Genentech, Inc. | 01/07/22 | 2D 3D TSV | |
US11072619 | 39 | 13 | HGNC:6190 HGNC:6192 HGNC:6193 | Pyrazole[1,5-a] pyrimidine derivatives as kinase JAK inhibitors | Celon Pharma S.A. | 01/07/22 | 2D 3D TSV |
US11072626 | 31 | 31 | HGNC:6563 | Small molecule inhibitors of Galectin-3 | Bristol-Myers Squibb Company | 01/07/22 | 2D 3D TSV |
US11071730 | 205 | 201 | HGNC:6863 | Substituted 6-azabenzimidazole compounds | Gilead Sciences, Inc. | 01/07/22 | 2D 3D TSV |
US11072582 | 277 | 275 | HGNC:4501 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | Epics Therapeutics | 01/07/22 | 2D 3D TSV |
US11046714 | 161 | 146 | HGNC:263 | 2,2-difluorodioxolo A2A receptor antagonists | Merck Sharp & Dohme Corp. | 12/28/21 | 2D 3D TSV |
US11046713 | 40 | 19 | HGNC:644 | Androgen receptor modulating compounds | ORION CORPORATION | 12/28/21 | 2D 3D TSV |
US11046725 | 52 | 26 | HGNC:6561 HGNC:6563 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB | 12/28/21 | 2D 3D TSV |
US11046712 | 181 | 175 | HGNC:7056 | Glycosidase inhibitors | Asceneuron SA | 12/28/21 | 2D 3D TSV |
US11046702 | 199 | 198 | HGNC:4597 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK BIOPHARMACEUTICALS CO., LTD. | 12/28/21 | 2D 3D TSV |
US11046710 | 48 | 48 | HGNC:438 | Sulfonamide compounds | Daiichi Sankyo Company, Limited; Sanford Burnham Prebys Medical Discovery Institute | 12/28/21 | 2D 3D TSV |
US11046662 | 48 | 45 | HGNC:12716 HGNC:497 HGNC:18083 HGNC:17961 | 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma | DOMPÉ FARMACEUTICI S.P.A. | 12/27/21 | 2D 3D TSV |
US11046691 | 749 | 729 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. | 12/27/21 | 2D 3D TSV | |
US11046646 | 10 | 5 | HGNC:3167 HGNC:3165 | Alkylphenyl compounds | Bristol-Myers Squibb Company | 12/27/21 | 2D 3D TSV |
US11046658 | 260 | 127 | HGNC:8978 HGNC:8977 | Aminopyrazine derivatives as PI3K-γ inhibitors | Incyte Corporation | 12/27/21 | 2D 3D TSV |
US11045455 | 135 | 26 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:6251 HGNC:2637 HGNC:2625 HGNC:12440 | Azetidine derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. | 12/27/21 | 2D 3D TSV |
US11046649 | 149 | 148 | HGNC:6059 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | Board of Regents, The University of Texas System | 12/27/21 | 2D 3D TSV |
US11046671 | 26 | 12 | HGNC:15631 HGNC:15632 | Dihydropyrimidinyl benzazepine carboxamide compounds | Hoffmann-La Roche Inc. | 12/27/21 | 2D 3D TSV |
US11046682 | 39 | 39 | HGNC:6059 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | Beijing Innocare Pharma Tech Co., Ltd | 12/27/21 | 2D 3D TSV |
US11046696 | 520 | 198 | HGNC:9967 | Fused pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 12/27/21 | 2D 3D TSV |
US11046680 | 486 | 436 | HGNC:339 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. | 12/27/21 | 2D 3D TSV |
US11046652 | 39 | 36 | Hydroxamic acids comprising pyrazole moiety and uses thereof | HAWAII BIOTECH, INC. | 12/27/21 | 2D 3D TSV | |
US11046672 | 414 | 70 | HGNC:8803 HGNC:3763 HGNC:6307 HGNC:8804 HGNC:3690 HGNC:3688 | Indolinones compounds and their use in the treatment of fibrotic diseases | RespiVert Limited | 12/27/21 | 2D 3D TSV |
US11046688 | 205 | 202 | HGNC:12401 | Inhibitor compounds | Cancer Research Technology Limited | 12/27/21 | 2D 3D TSV |
US11046651 | 75 | 35 | HGNC:3023 HGNC:5295 HGNC:5182 | Piperazine substituted azapine derivatives and uses thereof | ALAIRION, INC. | 12/27/21 | 2D 3D TSV |
US11046670 | 63 | 27 | HGNC:8157 | Piperazinyl norbenzomorphan compounds and methods for using the same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 12/27/21 | 2D 3D TSV |
US11045448 | 41 | 41 | HGNC:7010 | Piperidines as covalent menin inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 12/27/21 | 2D 3D TSV |
US11045457 | 445 | 208 | HGNC:11330 HGNC:11333 | Piperidinyl-3-(aryloxy)propanamides and propanoates | Takeda Pharmaceutical Company Limited | 12/27/21 | 2D 3D TSV |
US11046689 | 289 | 159 | HGNC:6251 HGNC:3467 | Selective estrogen receptor down-regulators | AstraZeneca AB | 12/27/21 | 2D 3D TSV |
US11046675 | 8 | 8 | Substituted isoquionline derivatives as immunomudulators | Bristol-Myers Squibb Company | 12/27/21 | 2D 3D TSV | |
US11046681 | 33 | 33 | HGNC:12630 | Substituted piperidines for the treatment of cancer | LES LABORATOIRES SERVIER; VERNALIS (R&D) LTD | 12/27/21 | 2D 3D TSV |
US11046698 | 1366 | 1145 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 12/27/21 | 2D 3D TSV | |
US11046686 | 30 | 30 | HGNC:17967 | Thiadiazole IRAK4 compounds | Gilead Sciences, Inc. | 12/27/21 | 2D 3D TSV |
US11066365 | 273 | 271 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Mission Therapeutics Limited | 12/23/21 | 2D 3D TSV | |
US11066414 | 981 | 964 | HGNC:3236 | Cot modulators and methods of use thereof | Gilead Sciences, Inc. | 12/23/21 | 2D 3D TSV |
US11066413 | 60 | 57 | HGNC:263 | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. | 12/20/21 | 2D 3D TSV |
US11066409 | 217 | 211 | HGNC:8537 | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. | 12/20/21 | 2D 3D TSV |
US11066404 | 6 | 6 | HGNC:1771 | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors | Incyte Corporation | 12/20/21 | 2D 3D TSV |
US11066406 | 60 | 15 | Small molecule inhibitors of the JAK family of kinases | Janssen Pharmaceutica NV | 12/20/21 | 2D 3D TSV | |
US11066396 | 1453 | 478 | HGNC:4852 HGNC:14064 HGNC:14068 HGNC:13315 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | MERCK SHARP & DOHME CORP. | 12/19/21 | 2D 3D TSV |
US11065253 | 471 | 329 | HGNC:9413 | Arylquinazolines | MERCK PATENT GMBH | 12/19/21 | 2D 3D TSV |
US11065231 | 55 | 55 | HGNC:17967 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. | 12/19/21 | 2D 3D TSV |
US11065249 | 32 | 26 | HGNC:16940 | Diacylglycerol acyl transferase 2 inhibitor | Pfizer Inc. | 12/19/21 | 2D 3D TSV |
US11066360 | 104 | 102 | HGNC:6371 | Human plasma kallikrein inhibitors | BioCryst Pharmaceuticals, Inc. | 12/19/21 | 2D 3D TSV |
US11066363 | 22 | 13 | HGNC:11305 HGNC:11306 | Substituted 6,11-dihydro-5H-benzo[B]carbazoles as inhibitors of ALK and SRPK | DANA-FARBER CANCER INSTITUTE, INC. | 12/19/21 | 2D 3D TSV |
US11040966 | 1982 | 987 | HGNC:4849 HGNC:4848 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD | 12/14/21 | 2D 3D TSV |
US11040034 | 272 | 135 | HGNC:2592 HGNC:2591 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. | 12/14/21 | 2D 3D TSV |
US11041859 | 70 | 10 | HGNC:17927 HGNC:30402 HGNC:23116 | Methods of identifying SENP1 inhibitors | CITY OF HOPE | 12/14/21 | 2D 3D TSV |
US11040968 | 17 | 17 | HGNC:6857 | Pyridine derivative as ASK1 inhibitor and preparation method and use thereof | TBA | 12/14/21 | 2D 3D TSV |
US11040984 | 22 | 11 | HGNC:3236 | Quinazoline compound for EGFR inhibition | MEDSHINE DISCOVERY INC. | 12/14/21 | 2D 3D TSV |
US11040980 | 33 | 32 | HGNC:1133 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | Principia Biopharma Inc. | 12/14/21 | 2D 3D TSV |
US11040979 | 20 | 4 | HGNC:6342 | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR | Blueprint Medicines Corporation | 12/14/21 | 2D 3D TSV |
US11040967 | 15 | 11 | HGNC:12440 | TYK2 inhibitors, uses, and methods for production thereof | Nimbus Lakshmi, Inc. | 12/14/21 | 2D 3D TSV |
US11040970 | 54 | 42 | HGNC:10935 | VMAT2 inhibitor compounds and compositions thereof | Neurocrine Biosciences, Inc. | 12/14/21 | 2D 3D TSV |
US11034715 | 248 | 146 | HGNC:8021 | Ectonucleotidase inhibitors and methods of use thereof | Calithera Biosciences, Inc. | 12/06/21 | 2D 3D TSV |
US11034717 | 33 | 11 | Farnesoid X receptor modulators | Intercept Pharmaceuticals, Inc. | 12/06/21 | 2D 3D TSV | |
US11034991 | 6 | 5 | HGNC:29079 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | Oryzon Genomics S.A. | 12/06/21 | 2D 3D TSV |
US11034671 | 100 | 99 | HGNC:6857 | Apoptosis signal-regulating kinase inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. | 12/05/21 | 2D 3D TSV |
US11033547 | 127 | 100 | HGNC:9644 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | Merck Patent GmbH | 12/05/21 | 2D 3D TSV |
US11033539 | 1210 | 551 | HGNC:1954 HGNC:1953 HGNC:1950 HGNC:1952 HGNC:1951 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | Neurocrine Biosciences, Inc. | 12/05/21 | 2D 3D TSV |
US11034678 | 17 | 16 | HGNC:16940 | Diacylglycerol acyl transferase 2 inhibitors | Pfizer Inc. | 12/05/21 | 2D 3D TSV |
US11034699 | 17 | 17 | HGNC:4596 | Ethynyl derivatives | Hoffmann-La Roche Inc. | 12/05/21 | 2D 3D TSV |
US11034705 | 52 | 52 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | Nikang Therapeutics, Inc. | 12/05/21 | 2D 3D TSV | |
US11034692 | 420 | 390 | HGNC:6863 | Naphthyridines as inhibitors of HPK1 | Genentech, Inc. | 12/05/21 | 2D 3D TSV |
US11034670 | 70 | 53 | HGNC:270 HGNC:272 | Poly-ADP ribose polymerase (PARP) inhibitors | Mitobridge, Inc. | 12/05/21 | 2D 3D TSV |
US11034698 | 115 | 94 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | Genentech, Inc. | 12/05/21 | 2D 3D TSV | |
US11034658 | 65 | 65 | Pyridinyl pyrazoles as modulators of RORγT | Janssen Pharmaceutica NV | 12/05/21 | 2D 3D TSV | |
US11034691 | 995 | 366 | HGNC:3169 HGNC:3167 HGNC:3165 HGNC:14299 HGNC:3170 | Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders | THE SCRIPPS RESEARCH INSTITUTE | 12/05/21 | 2D 3D TSV |
US11034661 | 67 | 67 | HGNC:6059 | Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors | Merck Sharp & Dohme Corp. | 12/05/21 | 2D 3D TSV |
US11034694 | 837 | 825 | HGNC:6863 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. | 12/05/21 | 2D 3D TSV |
US11028054 | 35 | 35 | HGNC:2867 | 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors | Merck Patent GmbH | 11/29/21 | 2D 3D TSV |
US11021493 | 720 | 166 | HGNC:934 HGNC:2529 HGNC:933 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | Amgen Inc. | 11/29/21 | 2D 3D TSV |
US11026923 | 606 | 192 | HGNC:8775 HGNC:8774 HGNC:8776 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. Lundbeck A/S | 11/29/21 | 2D 3D TSV |
US11028101 | 3 | 3 | HGNC:10894 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD | 11/29/21 | 2D 3D TSV |
US11028093 | 867 | 205 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC.; CELGENE CORPORATION | 11/29/21 | 2D 3D TSV |
US11021475 | 37 | 35 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | Bristol-Myers Squibb Company | 11/29/21 | 2D 3D TSV | |
US11021511 | 20 | 6 | Cyclic dinucleotides as sting agonists | Janssen Biotech, Inc. | 11/29/21 | 2D 3D TSV | |
US11028083 | 163 | 145 | HGNC:23393 HGNC:18241 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | Board of Regents, The University of Texas System | 11/29/21 | 2D 3D TSV |
US11026937 | 134 | 134 | HGNC:18368 | Heteroaryl inhibitors of PAD4 | Padlock Therapeutics, Inc. | 11/29/21 | 2D 3D TSV |
US11028067 | 15 | 7 | HGNC:12437 HGNC:4623 | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | Oblique Therapeutics AB | 11/29/21 | 2D 3D TSV |
US11028058 | 12 | 12 | HGNC:263 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. | 11/29/21 | 2D 3D TSV |
US11021478 | 24 | 23 | HGNC:1232 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL | 11/29/21 | 2D 3D TSV |
US11028066 | 97 | 97 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research, Inc. | 11/29/21 | 2D 3D TSV |
US11021467 | 405 | 131 | HGNC:8978 HGNC:8980 HGNC:8977 | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences, Inc. | 11/29/21 | 2D 3D TSV |
US11026936 | 57 | 34 | HGNC:8810 | Piperidinyl-propanone derivatives | Merck Patent GmbH | 11/29/21 | 2D 3D TSV |
US11028041 | 36 | 18 | HGNC:5253 | Second generation GRP94-selective inhibitors | University of Kansas | 11/29/21 | 2D 3D TSV |
US11026958 | 41 | 36 | HGNC:1960 | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | Merck Sharp & Dohme Corp. | 11/29/21 | 2D 3D TSV |
US11021481 | 837 | 812 | HGNC:6863 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. | 11/29/21 | 2D 3D TSV |
US11028085 | 837 | 823 | HGNC:6863 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | Nimbus Saturn, Inc. | 11/29/21 | 2D 3D TSV |
US11028092 | 124 | 60 | HGNC:8795 | Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors | Merck Sharp & Dohme Corp. | 11/29/21 | 2D 3D TSV |
US11028080 | 44 | 36 | Substituted pyrimidines as LRKK2 inhibitors | DENALI THERAPEUTICS INC. | 11/29/21 | 2D 3D TSV | |
US11028051 | 14 | 7 | Tetrahydroquinoline-based bromodomain inhibitors | St. Jude Children''s Research Hospital | 11/29/21 | 2D 3D TSV | |
US11028075 | 182 | 90 | HGNC:10597 | Therapeutic compounds and methods of use thereof | Genentech, Inc. | 11/29/21 | 2D 3D TSV |
US11021463 | 202 | 145 | HGNC:6371 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. | 11/29/21 | 2D 3D TSV |
US11021515 | 404 | 207 | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. | 11/29/21 | 2D 3D TSV | |
US11028064 | 146 | 76 | HGNC:6307 | Tricyclic heterocyclic derivatives and uses thereof | AUCKLAND UNISERVICES LIMITED | 11/29/21 | 2D 3D TSV |
US11028104 | 83 | 42 | HGNC:12008 HGNC:20692 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN; FORSCHUNGSVERBUND BERLIN E.V. | 11/29/21 | 2D 3D TSV |
US11028090 | 505 | 491 | HGNC:13575 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | Dong Wha Pharm. Co., Ltd.; Korea Research Institute of Chemical Technology | 11/29/21 | 2D 3D TSV |
US11020398 | 376 | 299 | HGNC:1133 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | ArQule, Inc. | 11/28/21 | 2D 3D TSV |
US11020381 | 174 | 169 | HGNC:10597 | Biaryloxy derivatives as TTX-S blockers | RaQualia Pharma Inc.; XuanZhu Pharma Co., Ltd. | 11/28/21 | 2D 3D TSV |
US11021457 | 150 | 150 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD. | 11/28/21 | 2D 3D TSV | |
US11020397 | 70 | 44 | HGNC:12805 HGNC:17989 | Compounds and their use for reducing uric acid levels | Acquist LLC | 11/28/21 | 2D 3D TSV |
US11020395 | 154 | 115 | HGNC:339 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AMGEN INC. | 11/28/21 | 2D 3D TSV |
US11020380 | 410 | 396 | HGNC:2348 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. | 11/28/21 | 2D 3D TSV |
US11021454 | 44 | 27 | HGNC:12805 | Type of aryl benzofuran amidated derivative and medical use thereof | CHINA PHARMACEUTICAL UNIVERSITY | 11/28/21 | 2D 3D TSV |
US11014905 | 114 | 36 | HGNC:3023 HGNC:5286 | 2,6-disubstituted pyridine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. | 11/22/21 | 2D 3D TSV |
US11014923 | 152 | 37 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 11/22/21 | 2D 3D TSV |
US11014911 | 1035 | 569 | HGNC:1780 HGNC:1771 HGNC:4617 HGNC:1777 HGNC:1722 HGNC:1773 | CDK2 inhibitors | Pfizer Inc. | 11/22/21 | 2D 3D TSV |
US11014912 | 68 | 68 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED | 11/22/21 | 2D 3D TSV | |
US11014920 | 36 | 35 | HGNC:3530 | Factor XIIa inhibitors | Merck Sharp & Dohme Corp. | 11/22/21 | 2D 3D TSV |
US11014930 | 78 | 78 | HGNC:9967 | Fused pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 11/22/21 | 2D 3D TSV |
US11014909 | 81 | 72 | HGNC:3020 | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc. | 11/22/21 | 2D 3D TSV |
US11013718 | 9 | 9 | HGNC:29079 | LSD1 inhibitors and medical uses thereof | Constellation Pharmaceuticals, Inc. | 11/22/21 | 2D 3D TSV |
US11014929 | 126 | 126 | HGNC:6863 | Pyrazolopyrimidine compounds and uses thereof | Incyte Corporation | 11/22/21 | 2D 3D TSV |
US11014913 | 855 | 800 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics, Inc. | 11/22/21 | 2D 3D TSV | |
US11014926 | 35 | 30 | HGNC:7110 HGNC:7111 | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 | eFFECTOR Therapeutics, Inc. | 11/22/21 | 2D 3D TSV |
US11013745 | 80 | 79 | Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES; SUZHOU SUPLEAD LIFE SCIENCES CO., LTD. | 11/22/21 | 2D 3D TSV | |
US11014963 | 205 | 202 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | Hoffmann-La Roche Inc. | 11/22/21 | 2D 3D TSV | |
US11008338 | 48 | 25 | HGNC:934 HGNC:933 | C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp. | 11/15/21 | 2D 3D TSV |
US11008314 | 623 | 155 | HGNC:1133 HGNC:6193 HGNC:6171 HGNC:12434 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | Corvus Pharmaceuticals, Inc. | 11/15/21 | 2D 3D TSV |
US11008336 | 22 | 8 | HGNC:10259 HGNC:10258 | Compounds useful for inhibiting RORγt | Eli Lilly and Company | 11/15/21 | 2D 3D TSV |
US11007200 | 16 | 8 | HGNC:8157 | Cycloalkyl-diamines for the treatment of pain | MediSynergics, LLC | 11/14/21 | 2D 3D TSV |
US11008301 | 42 | 21 | HGNC:3827 HGNC:3826 | Piperidinone formyl peptide 2 receptor agonists | Bristol-Myers Squibb Company | 11/14/21 | 2D 3D TSV |
US11008312 | 373 | 359 | Pyridazine derivatives as RORc modulators | Genentech, Inc. | 11/14/21 | 2D 3D TSV | |
US11008308 | 435 | 420 | HGNC:29232 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. | 11/14/21 | 2D 3D TSV |
US11008304 | 85 | 85 | HGNC:6857 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 11/14/21 | 2D 3D TSV |
US11000525 | 30 | 15 | HGNC:7218 HGNC:12015 | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | ASTRAZENECA AB | 11/08/21 | 2D 3D TSV |
US11001596 | 70 | 8 | HGNC:5383 HGNC:5382 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | Eli Lilly and Company | 11/08/21 | 2D 3D TSV |
US11001586 | 178 | 88 | HGNC:7027 HGNC:12446 | Alkyl pyrrolopyrimidine analogs and methods of making and using same | The University of North Carolina at Chapel Hill | 11/08/21 | 2D 3D TSV |
USRE48547 | 6 | 6 | HGNC:6027 | Aminopyrimidinecarboxamides as CXCR2 modulators | Syntrix Biosystems Inc. | 11/08/21 | 2D 3D TSV |
US11001575 | 923 | 899 | HGNC:6871 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. | 11/08/21 | 2D 3D TSV |
US11000528 | 26 | 11 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV | 11/08/21 | 2D 3D TSV | |
US10995099 | 93 | 59 | HGNC:85 HGNC:84 | Compounds and their uses as ACC inhibitors | Nanjing Ruijie Pharmatech Co., Ltd. | 11/08/21 | 2D 3D TSV |
US11000515 | 25 | 25 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | Shy Therapeutics LLC | 11/08/21 | 2D 3D TSV | |
US11001555 | 22 | 22 | Difluoroketamide derivatives as HTRA1 inhibitors | Hoffman-La Roche Inc. | 11/08/21 | 2D 3D TSV | |
US11001583 | 16 | 16 | Dihydropyrrolopyridine inhibitors of ROR-gamma | Vitae Pharmaceuticals, LLC | 11/08/21 | 2D 3D TSV | |
US11001600 | 13 | 13 | HGNC:2771 | Disubstituted compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. | 11/08/21 | 2D 3D TSV |
US11001568 | 170 | 44 | HGNC:29012 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. | 11/08/21 | 2D 3D TSV |
US11001578 | 188 | 92 | HGNC:6371 HGNC:6357 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED | 11/08/21 | 2D 3D TSV |
US11001589 | 51 | 51 | HGNC:3650 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB | 11/08/21 | 2D 3D TSV |
US11001595 | 32 | 13 | HGNC:3763 HGNC:2861 HGNC:6307 HGNC:8804 HGNC:3236 | Pyrimidine compounds and pyrimido indole compounds and methods of use | Duquesne University of The Holy Spirit | 11/08/21 | 2D 3D TSV |
US11001572 | 40 | 10 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Pyrimidine derivative, method for preparing same and use thereof in medicine | TBA | 11/08/21 | 2D 3D TSV |
US11001561 | 146 | 136 | HGNC:9644 | Pyrimidinone derivatives as SHP2 antagonists | Merck Patent GmbH | 11/08/21 | 2D 3D TSV |
US11001563 | 81 | 81 | HGNC:550 | SSAO inhibitor | TBA | 11/08/21 | 2D 3D TSV |
US10995070 | 15 | 15 | HGNC:84 | Acetyl-CoA carboxylase modulators | Monsanto Technology LLC | 11/04/21 | 2D 3D TSV |
US10994015 | 521 | 108 | HGNC:3430 HGNC:3431 HGNC:3236 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC.; YALE UNIVERSITY | 11/04/21 | 2D 3D TSV |
US10995072 | 124 | 57 | HGNC:3538 | Inhibitors of protease-activated receptor-2 | Heptares Therapeutics Limited | 11/04/21 | 2D 3D TSV |
US10995088 | 309 | 162 | HGNC:6833 HGNC:6834 HGNC:2671 HGNC:6664 HGNC:6666 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL | 11/04/21 | 2D 3D TSV |
US10995073 | 253 | 218 | HGNC:8605 HGNC:270 | PARG inhibitory compounds | Cancer Research Technology Limited | 11/04/21 | 2D 3D TSV |
US10995084 | 192 | 116 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. | 11/04/21 | 2D 3D TSV | |
US10995090 | 21 | 19 | HGNC:7056 | Substituted dihydrobenzofuran glycosidase inhibitors | Asceneuron SA | 11/04/21 | 2D 3D TSV |
US10995089 | 92 | 92 | HGNC:6871 | Zaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE DE MONTPELLIER | 11/04/21 | 2D 3D TSV |
US10988455 | 108 | 53 | HGNC:262 HGNC:263 | 1,2,4-triazine-4-amine derivatives | Heptares Therapeutics Limited | 11/01/21 | 2D 3D TSV |
US10988502 | 64 | 32 | HGNC:6561 HGNC:6563 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB | 11/01/21 | 2D 3D TSV |
US10988458 | 71 | 70 | HGNC:6857 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 11/01/21 | 2D 3D TSV |
US10988459 | 91 | 77 | Bicyclic lactams and methods of use thereof | Genentech, Inc. | 11/01/21 | 2D 3D TSV | |
US10988445 | 310 | 136 | Compounds | AstraZeneca AB | 11/01/21 | 2D 3D TSV | |
US10988482 | 108 | 99 | HGNC:17967 | IRAK4 inhibitor and use thereof | BEIJING HANMI PHARMACEUTICAL CO., LTD. | 11/01/21 | 2D 3D TSV |
US10988507 | 2 | 2 | Immunomodulators | bristol-myers squibb company | 11/01/21 | 2D 3D TSV | |
US10987354 | 24 | 23 | Inhibitors of influenza virus replication and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. | 11/01/21 | 2D 3D TSV | |
US10988451 | 457 | 440 | MCL-1 inhibitors | Gilead Sciences, Inc. | 11/01/21 | 2D 3D TSV | |
US10988481 | 66 | 20 | HGNC:8153 HGNC:8154 HGNC:8156 | Potent and selective mu opioid receptor modulators | Virginia Commonwealth University | 11/01/21 | 2D 3D TSV |
US10988462 | 37 | 37 | HGNC:11036 | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof | Japan Tobacco Inc. | 11/01/21 | 2D 3D TSV |
US10988478 | 551 | 532 | HGNC:17967 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | Genentech, Inc. | 11/01/21 | 2D 3D TSV |
US10988463 | 79 | 55 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | Pfizer Inc. | 11/01/21 | 2D 3D TSV | |
US10988487 | 242 | 204 | HGNC:6059 | Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | Merck Sharp & Dohme Corp. | 11/01/21 | 2D 3D TSV |
US10988476 | 635 | 140 | HGNC:1780 HGNC:1771 HGNC:1778 HGNC:1722 HGNC:1777 HGNC:1774 HGNC:1773 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. | 11/01/21 | 2D 3D TSV |
US10981917 | 230 | 229 | HGNC:9462 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | Daewoong Pharmaceutical Co., Ltd. | 10/27/21 | 2D 3D TSV |
US10981916 | 25 | 25 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC | 10/27/21 | 2D 3D TSV | |
US10981926 | 3 | 1 | HGNC:7978 HGNC:644 | Substituted thiohydantoin derivatives as androgen receptor antagonists | Janssen Pharmaceutica NV | 10/27/21 | 2D 3D TSV |
US10981914 | 16 | 11 | HGNC:15631 HGNC:6018 | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor | Bristol-Myers Squibb Companay | 10/27/21 | 2D 3D TSV |
US10981904 | 67 | 61 | 1,3,4-thiadiazole compounds and their use in treating cancer | Cancer Research Technology Limited | 10/26/21 | 2D 3D TSV | |
US10980781 | 21 | 18 | HGNC:12630 | 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use | Purdue Research Foundation | 10/26/21 | 2D 3D TSV |
US10980815 | 468 | 113 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Aminopyrimidinyl compounds | Pfizer Inc. | 10/26/21 | 2D 3D TSV |
US10981887 | 50 | 25 | HGNC:3467 | Benzothiophene estrogen receptor modulators | G1 Therapeutics, Inc. | 10/26/21 | 2D 3D TSV |
US10981910 | 237 | 236 | HGNC:19679 | Biaryl kinase inhibitors | Bristol-Myers Squibb Company | 10/26/21 | 2D 3D TSV |
US10981882 | 19 | 19 | HGNC:6059 | Compound for inhibiting IDO, a manufacturing method and a use thereof | Shanghai JOYU Pharmatech Ltd. | 10/26/21 | 2D 3D TSV |
US10981881 | 16 | 8 | HGNC:7967 | FXR (NR1H4) modulating compounds | Gilead Sciences, Inc. | 10/26/21 | 2D 3D TSV |
US10981905 | 154 | 49 | HGNC:10593 HGNC:10585 HGNC:10596 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | Xenon Pharmaceuticals Inc. | 10/26/21 | 2D 3D TSV |
US10981911 | 840 | 210 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | Janssen Pharmaceutica NV | 10/26/21 | 2D 3D TSV | |
US10981896 | 43 | 22 | HGNC:16870 HGNC:1925 HGNC:1470 HGNC:9377 HGNC:14311 HGNC:6871 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 10/26/21 | 2D 3D TSV |
US10981899 | 9 | 5 | HGNC:21285 | Inhibitors of soluble adenylyl cyclase | Cornell University; Tri-Institutional Therapeutics Discovery Institute | 10/26/21 | 2D 3D TSV |
US10981898 | 89 | 85 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED | 10/26/21 | 2D 3D TSV | |
US10980794 | 334 | 329 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. | 10/26/21 | 2D 3D TSV | |
US10981906 | 110 | 51 | HGNC:6190 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. | 10/26/21 | 2D 3D TSV |
US10981893 | 35 | 30 | HGNC:6371 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. | 10/26/21 | 2D 3D TSV |
US10981879 | 189 | 164 | HGNC:7218 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | Bristol-Myers Squibb Company | 10/26/21 | 2D 3D TSV |
US10980809 | 132 | 95 | HGNC:6307 HGNC:9829 HGNC:1097 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED | 10/26/21 | 2D 3D TSV |
US10975062 | 135 | 135 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | TBA | 10/20/21 | 2D 3D TSV | |
US10975057 | 94 | 92 | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT | Janssen Pharmaceutica NV | 10/20/21 | 2D 3D TSV | |
US10975068 | 453 | 440 | 6-aminopyridin-3-yl thiazoles as modulators of RORγT | Janssen Pharmaceutica NV | 10/20/21 | 2D 3D TSV | |
US10975066 | 25 | 25 | HGNC:11138 | Bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL | 10/20/21 | 2D 3D TSV |
US10975080 | 72 | 71 | HGNC:9644 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG | 10/20/21 | 2D 3D TSV |
US10975030 | 28 | 28 | HGNC:5253 | Grp94 selective inhibitors and uses thereof | University of Kansas; University of South Florida | 10/20/21 | 2D 3D TSV |
US10975075 | 471 | 134 | HGNC:8978 HGNC:795 HGNC:8975 HGNC:3942 HGNC:8977 HGNC:8976 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | Merck Patent GmbH | 10/20/21 | 2D 3D TSV |
US10975058 | 8 | 4 | HGNC:4840 HGNC:1133 | Imidazolyl kinase inhibitors and uses thereof | Dana-Farber Cancer Institute, Inc. | 10/20/21 | 2D 3D TSV |
US10975084 | 185 | 185 | HGNC:18039 | KDM5 inhibitors | Merck Sharp & Dohme Corp. | 10/20/21 | 2D 3D TSV |
US10975049 | 22 | 22 | Nicotinyl alcohol ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof | Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD | 10/20/21 | 2D 3D TSV | |
US10973817 | 147 | 146 | HGNC:1925 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED | 10/20/21 | 2D 3D TSV |
US10975037 | 228 | 225 | Phenyl substituted pyrazoles as modulators of RORγt | Janssen Pharmaceutica NV | 10/20/21 | 2D 3D TSV | |
US10975091 | 290 | 150 | HGNC:6656 | Pyridine derivative | Astellas Pharma Inc.; KOTOBUKI PHARMACEUTICAL CO., LTD. | 10/20/21 | 2D 3D TSV |
US10975064 | 27 | 27 | RIP1 inhibitory compounds and methods for making and using the same | Rigel Pharmaceuticals, Inc. | 10/20/21 | 2D 3D TSV | |
US10975081 | 18 | 16 | HGNC:18618 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 10/20/21 | 2D 3D TSV |
US10975056 | 659 | 644 | HGNC:2976 | Substituted pyridines as inhibitors of DNMT1 | GlaxoSmithKline Intellectual Property Development Limited; Cancer Research Technology Ltd. | 10/20/21 | 2D 3D TSV |
US10968216 | 332 | 297 | HGNC:2867 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; THE BROAD INSTITUTE, INC.; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE GENERAL HOSPITAL CORPORATION | 10/09/21 | 2D 3D TSV |
US10968163 | 97 | 34 | HGNC:3560 HGNC:3557 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | The Research Foundation for the State University of New York | 10/09/21 | 2D 3D TSV |
US10968188 | 153 | 114 | HGNC:8803 HGNC:76 HGNC:6342 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1st Biotherapeutics, Inc. | 10/09/21 | 2D 3D TSV |
US10968198 | 35 | 35 | HGNC:7097 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | Yale University | 10/09/21 | 2D 3D TSV |
US10968199 | 30 | 29 | HGNC:6857 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 10/09/21 | 2D 3D TSV |
US10968242 | 106 | 35 | Cyclopentane-based modulators of STING (stimulator of interferon genes) | Pfizer Inc. | 10/09/21 | 2D 3D TSV | |
US10968213 | 375 | 107 | HGNC:6833 HGNC:6834 HGNC:29079 | Cyclopropanamine compound and use thereof | Takeda Pharmaceutical Company Limited | 10/09/21 | 2D 3D TSV |
US10968223 | 155 | 155 | HGNC:550 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | Proximagen, LLC | 10/09/21 | 2D 3D TSV |
US10968227 | 45 | 45 | HGNC:4596 | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | Vanderbilt University | 10/09/21 | 2D 3D TSV |
US10966985 | 52 | 13 | HGNC:10261 | Macrocyclic compounds as ROS1 kinase inhibitors | Array BioPharma Inc. | 10/09/21 | 2D 3D TSV |
US10968215 | 227 | 189 | HGNC:3527 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 10/09/21 | 2D 3D TSV |
US10966980 | 1100 | 273 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrrolo[2,3-d]pyrimidine derivatives | Pfizer Inc. | 10/09/21 | 2D 3D TSV |
US10968221 | 13 | 13 | HGNC:29079 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors | Incyte Corporation | 10/09/21 | 2D 3D TSV |
US10967060 | 22 | 22 | HGNC:6059 | Synergistic combination of immunologic inhibitors for the treatment of cancer | The University of Chicago | 10/09/21 | 2D 3D TSV |
US10968236 | 184 | 91 | HGNC:6192 HGNC:12440 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 10/09/21 | 2D 3D TSV |
US10966987 | 23 | 23 | HGNC:6307 | Therapeutic compounds and uses thereof | Kala Pharmaceuticals, Inc. | 10/09/21 | 2D 3D TSV |
US10968172 | 90 | 90 | USP30 inhibitors | Mitobridge, Inc. | 10/09/21 | 2D 3D TSV | |
US10961236 | 249 | 63 | HGNC:8975 HGNC:8977 HGNC:8976 | (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor | AstraZeneca AB | 10/04/21 | 2D 3D TSV |
US10961241 | 73 | 66 | Chemical compounds | AstraZeneca AB | 10/04/21 | 2D 3D TSV | |
US10961242 | 81 | 80 | HGNC:3357 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LegoChem Biosciences, Inc. | 10/04/21 | 2D 3D TSV |
US10961198 | 66 | 66 | HGNC:7967 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. | 10/04/21 | 2D 3D TSV |
US10961237 | 146 | 145 | HGNC:1133 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. | 10/04/21 | 2D 3D TSV |
US10961228 | 198 | 66 | JAK1 selective inhibitors | ASTRAZENECA AB | 10/04/21 | 2D 3D TSV | |
US10961249 | 21 | 21 | Modulators of the sigma-2 receptor and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 10/04/21 | 2D 3D TSV | |
US10961233 | 46 | 45 | Oxazole derivatives for use in the treatment of cancer | LIFEARC | 10/04/21 | 2D 3D TSV | |
US10961256 | 3 | 3 | HGNC:10894 | PRMT5 inhibitors | CTXT PTY LTD | 10/04/21 | 2D 3D TSV |
US10961247 | 365 | 180 | HGNC:1133 HGNC:6193 | Pyrazolopyrimidine derivatives as kinase inhibitor | Daewoong Pharmaceutical Co., Ltd. | 10/04/21 | 2D 3D TSV |
US10961252 | 34 | 34 | HGNC:1037 | Quinazoline and indole compounds to treat medical disorders | Achillion Pharmaceuticals, Inc. | 10/04/21 | 2D 3D TSV |
US10961200 | 522 | 512 | HGNC:6535 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; VANDERBILT UNIVERSITY; THE UAB RESEARCH FOUNDATION; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 10/04/21 | 2D 3D TSV |
US10961232 | 603 | 568 | HGNC:882 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 10/04/21 | 2D 3D TSV |
US10960005 | 122 | 119 | HGNC:29079 | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. | 10/04/21 | 2D 3D TSV |
US10954228 | 149 | 145 | HGNC:6535 | 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE UAB RESEARCH FOUNDATION; VANDERBILT UNIVERSITY; NATIONAL INSTITUTES OF HEALTH, UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES | 09/28/21 | 2D 3D TSV |
US10954253 | 76 | 75 | HGNC:12761 | 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor | SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD. | 09/28/21 | 2D 3D TSV |
US10952995 | 27 | 27 | HGNC:6863 | Azaindoles as inhibitors of HPK1 | Genentech, Inc. | 09/28/21 | 2D 3D TSV |
US10954216 | 119 | 90 | HGNC:171 | BMP-signal-inhibiting compound | RIKEN; THE UNIVERSITY OF TOKYO | 09/28/21 | 2D 3D TSV |
US10954244 | 11 | 11 | HGNC:6307 | Compounds and uses thereof | Kala Pharmaceuticals, Inc. | 09/28/21 | 2D 3D TSV |
US10954240 | 60 | 60 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | Merck Sharp & Dohme Corp. | 09/28/21 | 2D 3D TSV | |
US10954241 | 320 | 108 | HGNC:6307 HGNC:9967 | Heterocyclic compounds as ret kinase inhibitors | Cancer Research Technology Limited | 09/28/21 | 2D 3D TSV |
US10953012 | 420 | 239 | HGNC:2459 | Heterocyclic compounds for the inhibition of pask | BioEnergenix LLC | 09/28/21 | 2D 3D TSV |
US10954237 | 56 | 19 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | JAK inhibitors containing a 4-membered heterocyclic amide | Theravance Biopharma R&D IP, LLC | 09/28/21 | 2D 3D TSV |
US10947254 | 1048 | 261 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | Theravance Biopharma R&D IP, LLC | 09/28/21 | 2D 3D TSV |
US10952992 | 100 | 97 | HGNC:9665 | Methods of treating intraocular pressure with activators of Tie-2 | AERPIO PHARMACEUTICALS, INC. | 09/28/21 | 2D 3D TSV |
US10954214 | 449 | 444 | HGNC:6819 | Pyrazole derivatives as MALT1 inhibitors | Janssen Pharmaceutica NV | 09/28/21 | 2D 3D TSV |
US10954225 | 28 | 15 | Selective NR2B antagonists | Bristol-Myers Squibb Company | 09/28/21 | 2D 3D TSV | |
US10954217 | 86 | 43 | HGNC:8157 | Sigma receptor binders | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 09/28/21 | 2D 3D TSV |
US10954243 | 22 | 22 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. | 09/28/21 | 2D 3D TSV | |
US10954193 | 147 | 134 | HGNC:6943 HGNC:992 HGNC:990 | Substituted indole Mcl-1 inhibitors | Vanderbilt University | 09/28/21 | 2D 3D TSV |
US10953005 | 1229 | 556 | HGNC:9967 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Array Biopharma Inc. | 09/28/21 | 2D 3D TSV |
US10947203 | 176 | 88 | HGNC:7968 | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor | ST. JUDE CHILDREN''S RSEARCH HOSPITAL | 09/26/21 | 2D 3D TSV |
US10947218 | 616 | 87 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG | 09/26/21 | 2D 3D TSV | |
US10947196 | 8 | 4 | HGNC:285 HGNC:286 | Beta adrenergic agonist and methods of using the same | CuraSen Therapeutics, Inc. | 09/26/21 | 2D 3D TSV |
US10947230 | 162 | 54 | HGNC:3690 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR inhibitors | Incyte Corporation; Incyte Holdings Corporation | 09/26/21 | 2D 3D TSV |
US10947226 | 23 | 23 | Bicyclic pyridone lactams and methods of use thereof | Genentech, Inc. | 09/26/21 | 2D 3D TSV | |
US10945994 | 17 | 3 | HGNC:11708 HGNC:6059 | Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body | Pfizer Inc.; iTEOS THERAPEUTICS | 09/26/21 | 2D 3D TSV |
US10947229 | 48 | 12 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Dimethyl amino azetidine amides as JAK inhibitors | Theravance Biopharma R&D IP, LLC | 09/26/21 | 2D 3D TSV |
US10947243 | 391 | 79 | HGNC:11390 HGNC:4617 HGNC:3765 | Heteroaryl SYK inhibitors | Boehringer Ingelheim International GmbH | 09/26/21 | 2D 3D TSV |
US10947215 | 458 | 449 | Heteroaryl compounds and their use as therapeutic drugs | Dong-A Socio Holdings Co., Ltd. | 09/26/21 | 2D 3D TSV | |
US10947222 | 72 | 72 | HGNC:16940 | Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | Merck Sharp & Dohme Corp. | 09/26/21 | 2D 3D TSV |
US10947210 | 164 | 135 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. | 09/26/21 | 2D 3D TSV | |
US10947252 | 558 | 547 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | Janssen Pharmaceutica NV | 09/26/21 | 2D 3D TSV | |
US10946019 | 33 | 33 | HGNC:10477 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | TBA | 09/26/21 | 2D 3D TSV |
US10947234 | 36 | 12 | HGNC:10894 | PRMT5 inhibitors | Merck Sharp & Dohme Corp. | 09/26/21 | 2D 3D TSV |
US10947241 | 26 | 26 | Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same | Seoul National University Hospital | 09/26/21 | 2D 3D TSV | |
US10947223 | 72 | 18 | HGNC:2529 HGNC:933 | Substituted oxazines as beta-secretase inhibitors | Amgen Inc. | 09/26/21 | 2D 3D TSV |
US10946017 | 22 | 11 | HGNC:11584 | Tank-binding kinase-1 PROTACs and associated methods of use | ARVINAS OPERATIONS, INC. | 09/26/21 | 2D 3D TSV |
US10947251 | 76 | 38 | HGNC:10597 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. | 09/26/21 | 2D 3D TSV |
US10946023 | 1073 | 391 | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. | 09/26/21 | 2D 3D TSV | |
US10945978 | 12 | 6 | Treatment and diagnosis of melanoma | The Rockefeller University | 09/26/21 | 2D 3D TSV | |
US10947239 | 8 | 1 | HGNC:8778 | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound | Janssen Pharmaceutica NV | 09/26/21 | 2D 3D TSV |
US10941129 | 26 | 26 | Benzyl phenyl ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof | Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD | 09/20/21 | 2D 3D TSV | |
US10941160 | 505 | 499 | HGNC:13575 | Bromodomain inhibitors | Celgene Quanticel Research, Inc. | 09/20/21 | 2D 3D TSV |
US10941151 | 50 | 29 | HGNC:11526 HGNC:11527 HGNC:11528 | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof | Ogeda SA | 09/20/21 | 2D 3D TSV |
US10940139 | 25 | 25 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | Shy Therapeutics LLC | 09/20/21 | 2D 3D TSV | |
US10941162 | 32 | 8 | HGNC:8978 HGNC:8980 HGNC:8975 HGNC:8977 | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. | 09/20/21 | 2D 3D TSV |
US10941115 | 196 | 72 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6524 HGNC:6876 | Kinase inhibitors | Oxular Acquisitions Limited | 09/20/21 | 2D 3D TSV |
US10941146 | 31 | 31 | Methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC.; CORNELL UNIVERSITY | 09/20/21 | 2D 3D TSV | |
US10941138 | 193 | 88 | HGNC:1399 | Quinoline and isoquinoline derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. | 09/20/21 | 2D 3D TSV |
US10934296 | 665 | 131 | HGNC:6735 HGNC:4037 HGNC:1133 HGNC:11283 HGNC:6524 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | Merck Sharp & Dohme B.V. | 09/12/21 | 2D 3D TSV |
US10934297 | 286 | 143 | HGNC:4617 HGNC:3091 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | Samumed, LLC | 09/12/21 | 2D 3D TSV |
US10934303 | 124 | 28 | HGNC:3474 HGNC:3473 HGNC:3471 HGNC:3467 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION; KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL; KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION | 09/12/21 | 2D 3D TSV |
US10933063 | 258 | 214 | HGNC:6735 HGNC:1133 HGNC:6171 HGNC:11719 HGNC:3236 HGNC:6524 | Bruton's tyrosine kinase inhibitors | Suzhou Baijibugong Pharmaceutical Technology Co., Ltd. | 09/12/21 | 2D 3D TSV |
US10934285 | 61 | 61 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG | 09/12/21 | 2D 3D TSV | |
US10934310 | 484 | 472 | HGNC:1133 | Inhibitors of Bruton's tyrosine kinase and method of their use | Janssen Pharmaceutica NV | 09/12/21 | 2D 3D TSV |
US10934288 | 241 | 236 | HGNC:6863 | Pyrazolopyridine compounds and uses thereof | Incyte Corporation | 09/12/21 | 2D 3D TSV |
US10934305 | 54 | 32 | HGNC:10852 HGNC:10850 | SHMT inhibitors | The Trustees of Princeton University | 09/12/21 | 2D 3D TSV |
US10934302 | 294 | 288 | SHP2 phosphatase inhibitors and methods of use thereof | Relay Therapeutics, Inc. | 09/12/21 | 2D 3D TSV | |
US10934304 | 88 | 87 | HGNC:6871 | Spirocyclic compounds | Recurium IP Holdings, LLC | 09/12/21 | 2D 3D TSV |
US10934294 | 124 | 60 | Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors | Merck Sharp & Dohme Corp. | 09/12/21 | 2D 3D TSV | |
US10927106 | 45 | 44 | HGNC:3091 | Benzothiazole derivatives as DYRK1 inhibitors | PHARMASUM THERAPEUTICS AS | 09/06/21 | 2D 3D TSV |
US10927120 | 50 | 45 | HGNC:1771 HGNC:1773 | CDK inhibitors | GI Therapeutics, Inc. | 09/06/21 | 2D 3D TSV |
US10927110 | 31 | 31 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED | 09/06/21 | 2D 3D TSV | |
US10927076 | 96 | 48 | HGNC:5258 HGNC:5253 | HSP90B N-terminal isoform-selective inhibitors | University of Kansas | 09/06/21 | 2D 3D TSV |
US10927111 | 79 | 62 | HGNC:9829 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. | 09/06/21 | 2D 3D TSV |
US10927079 | 74 | 69 | HGNC:8031 | Intermediate compound of novel tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. | 09/06/21 | 2D 3D TSV |
US10927123 | 36 | 35 | HGNC:288 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | Arena Pharmaceuticals, Inc. | 09/06/21 | 2D 3D TSV |
US10927128 | 113 | 112 | HGNC:575 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. | 09/06/21 | 2D 3D TSV |
US10927105 | 323 | 248 | HGNC:17038 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 09/06/21 | 2D 3D TSV |
US10927086 | 86 | 48 | HGNC:6059 | Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | Merck Sharp & Dohme Corp. | 09/06/21 | 2D 3D TSV |
US10925881 | 14 | 7 | Treatment of conditions associated with hyperinsulinaemia | Tensha Therapeutics, Inc. | 09/06/21 | 2D 3D TSV | |
US10925840 | 52 | 26 | HGNC:285 HGNC:286 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | The USA, as represented by the Secretary, Department of Health and Human Services; SRI International | 09/06/21 | 2D 3D TSV |
US10919884 | 8 | 8 | HGNC:2771 | Amide compounds for treatment of immune and inflammatory disorders | Achillion Pharmaceuticals, Inc. | 09/02/21 | 2D 3D TSV |
US10918640 | 19 | 18 | HGNC:3553 | Azetidine derivatives | Vernalis (R&D) Ltd. | 09/02/21 | 2D 3D TSV |
US10919859 | 57 | 56 | HGNC:4498 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 09/02/21 | 2D 3D TSV |
US10919843 | 18 | 9 | HGNC:4910 | Cannabidiol derivatives as inhibitors of the HIF prolyl hydroxylases activity | Emerald Health Pharmaceuticals Inc. | 09/02/21 | 2D 3D TSV |
US10919885 | 926 | 463 | HGNC:10571 HGNC:21088 | Compounds and uses thereof | Yumanity Therapeutics, Inc. | 09/02/21 | 2D 3D TSV |
US10919856 | 36 | 18 | Cyclohexene compounds and use thereof | GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. | 09/02/21 | 2D 3D TSV | |
US10919862 | 9 | 6 | Fused imidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT | 09/02/21 | 2D 3D TSV | |
US10919902 | 46 | 23 | HGNC:4852 HGNC:4853 | Hetero-halo inhibitors of histone deacetylase | Alkermes, Inc. | 09/02/21 | 2D 3D TSV |
US10919914 | 6 | 3 | HGNC:8978 HGNC:8977 | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. | 09/02/21 | 2D 3D TSV |
US10919901 | 5 | 5 | HGNC:7029 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | Incyte Holdings Corporation; Incyte Corporation | 09/02/21 | 2D 3D TSV |
US10919899 | 20 | 12 | HGNC:1133 HGNC:6171 HGNC:11719 HGNC:12434 | Imidazopyrazine compounds, preparation methods and uses thereof | DONGGUAN ZHENXING-BEITE MEDICINE TECHNOLOGY CO., LTD. | 09/02/21 | 2D 3D TSV |
US10919852 | 416 | 407 | Immunomodulator compounds | ChemoCentryx, Inc. | 09/02/21 | 2D 3D TSV | |
US10918642 | 68 | 68 | HGNC:3255 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | Nerviano Medical Sciences S.R.L. | 09/02/21 | 2D 3D TSV |
US10919890 | 4 | 1 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV | 09/02/21 | 2D 3D TSV |
US10919913 | 67 | 56 | HGNC:6973 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | Boehringer Ingelheim International GmbH | 09/02/21 | 2D 3D TSV |
US10918645 | 91 | 51 | HGNC:6192 | Substituted tricyclic heterocyclic compounds and use thereof | LIFEARC; SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD. | 09/02/21 | 2D 3D TSV |
US10919869 | 50 | 49 | HGNC:2867 | Thiazole derivative and applications | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY | 09/02/21 | 2D 3D TSV |
US10919858 | 71 | 70 | HGNC:17989 | Thioacetate compounds, compositions and methods of use | Ardea Biosciences, Inc | 09/02/21 | 2D 3D TSV |
US10919895 | 66 | 37 | HGNC:15631 HGNC:6018 | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor | Bristol-Myers Squibb Company | 09/02/21 | 2D 3D TSV |
US10919911 | 81 | 80 | HGNC:6857 | Tricyclic ASK1 inhibitors | TERNS, INC. | 09/02/21 | 2D 3D TSV |
US10913710 | 100 | 99 | HGNC:8788 | Benzene disulfonamide for the treatment of cancer | Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V | 08/30/21 | 2D 3D TSV |
US10913735 | 14 | 14 | HGNC:11138 | Bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL | 08/30/21 | 2D 3D TSV |
US10912773 | 302 | 107 | HGNC:8775 HGNC:8774 HGNC:8776 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. Lundbeck A/S | 08/30/21 | 2D 3D TSV |
US10913740 | 112 | 16 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | JAK kinase inhibitor compounds for treatment of respiratory disease | Theravance Biopharma R&D IP, LLC | 08/30/21 | 2D 3D TSV |
US10913744 | 54 | 20 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. | 08/30/21 | 2D 3D TSV | |
US10913745 | 49 | 47 | HGNC:10548 | Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | Hoffmann-La Roche Inc. | 08/30/21 | 2D 3D TSV |
US10913742 | 110 | 110 | HGNC:497 | Oxadiazolones as transient receptor potential channel inhibitors | Genentech, Inc. | 08/30/21 | 2D 3D TSV |
US10913711 | 189 | 59 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 08/30/21 | 2D 3D TSV | |
US10912774 | 144 | 67 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. | 08/30/21 | 2D 3D TSV |
US10913746 | 124 | 111 | HGNC:9922 | Substituted 4-phenylpiperidines, their preparation and use | The Trustees of Columbia University in the City of New York | 08/30/21 | 2D 3D TSV |
US10913733 | 54 | 50 | HGNC:7056 | Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp. | 08/30/21 | 2D 3D TSV |
US10913753 | 410 | 219 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. | 08/30/21 | 2D 3D TSV | |
US10905688 | 302 | 111 | HGNC:8775 HGNC:8774 HGNC:8776 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | H. Lundbeck A/S | 08/22/21 | 2D 3D TSV |
US10906896 | 132 | 42 | HGNC:77 HGNC:76 HGNC:6342 | Compositions and methods for inhibiting kinases | Inhibikase Therapeutics, Inc. | 08/22/21 | 2D 3D TSV |
US10906900 | 62 | 14 | HGNC:11138 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE D''ORLEANS; UNIVERSITE DE TOURS; CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) | 08/22/21 | 2D 3D TSV |
US10906905 | 88 | 52 | HGNC:6307 HGNC:6876 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 08/22/21 | 2D 3D TSV |
US10906920 | 68 | 65 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 08/22/21 | 2D 3D TSV | |
US10906878 | 7 | 7 | HGNC:1133 | Kinase inhibitors for the treatment of disease | DANA FARBER CANCER INSTITUTE, INC. | 08/22/21 | 2D 3D TSV |
US10906888 | 205 | 198 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | Pfizer Inc. | 08/22/21 | 2D 3D TSV | |
US10905687 | 20 | 20 | Substituted piperazines as ROR-gamma modulators | ESCALIER BIOSCIENCES B.V. | 08/22/21 | 2D 3D TSV | |
US10906915 | 372 | 370 | HGNC:8783 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | LEO Pharma A/S | 08/22/21 | 2D 3D TSV |
US10906890 | 112 | 103 | HGNC:339 | Triazole phenyl compounds as agonists of the APJ receptor | AMGEN INC. | 08/22/21 | 2D 3D TSV |
US10899772 | 34 | 34 | HGNC:17967 | IRAK4 modulators | Genentech, Inc. | 08/16/21 | 2D 3D TSV |
US10899774 | 71 | 71 | HGNC:17967 | IRAK4 modulators | Genentech, Inc. | 08/16/21 | 2D 3D TSV |
US10899741 | 9 | 4 | HGNC:6307 HGNC:10020 HGNC:6876 | 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 08/15/21 | 2D 3D TSV |
US10899755 | 32 | 32 | HGNC:6863 | Benzothiazole compounds and uses thereof | Incyte Corporation | 08/15/21 | 2D 3D TSV |
US10899764 | 56 | 33 | HGNC:11708 HGNC:6059 | Imidazo isoindole derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD.; SHANGHAI HENGRUI PHRMACEUTICAL CO., LTD. | 08/15/21 | 2D 3D TSV |
US10899769 | 268 | 124 | Imidazopiperazinone inhibitors of transcription activating proteins | Board of Regents, The University of Texas System | 08/15/21 | 2D 3D TSV | |
US10899753 | 110 | 110 | HGNC:1133 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. | 08/15/21 | 2D 3D TSV |
US10899735 | 432 | 427 | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. | 08/15/21 | 2D 3D TSV | |
US10899756 | 28 | 23 | HGNC:8784 HGNC:8785 | Phosphodiesterase inhibitors and uses thereof | The Trustees of Columbia University in the City of New York | 08/15/21 | 2D 3D TSV |
US10899738 | 386 | 378 | HGNC:7010 | Piperidines as menin inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 08/15/21 | 2D 3D TSV |
US10898481 | 73 | 38 | HGNC:262 HGNC:263 HGNC:264 | Pyrazine compounds and uses thereof | TBA | 08/15/21 | 2D 3D TSV |
US10894048 | 73 | 49 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Antitumor drug for intermittent administration of FGFR inhibitor | Taiho Pharmaceutical Co., Ltd. | 08/14/21 | 2D 3D TSV |
US10894797 | 52 | 51 | HGNC:9644 | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors | Nikang Therapeutics, Inc. | 08/14/21 | 2D 3D TSV |
US10894789 | 334 | 165 | HGNC:4849 HGNC:4848 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB; EOLAS THERAPEUTICS, INC. | 08/14/21 | 2D 3D TSV |
US10894784 | 652 | 648 | HGNC:11584 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT | 08/14/21 | 2D 3D TSV |
US10894052 | 36 | 35 | Heterocyclic inhibitors of ATR kinase | Board of Regents, The University of Texas System; ChemPartner Corporation | 08/14/21 | 2D 3D TSV | |
US10894038 | 20 | 19 | HGNC:17989 | Indolizine derivatives, composition and methods of use | SHANGHAI FOCHON PHARMACEUTICAL CO. LTD.; FOCHON PHARMACEUTICALS, LTD. | 08/14/21 | 2D 3D TSV |
US10894788 | 199 | 161 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. | 08/14/21 | 2D 3D TSV | |
US10894782 | 132 | 120 | HGNC:12666 | Modulators of P97 AAA ATPase activity | University of Pittsburgh—Of the Commonwealth System of Higher Education | 08/14/21 | 2D 3D TSV |
US10894803 | 4 | 4 | HGNC:5467 | Multi-functionalized polysaccharide compounds and use thereof for targeting the cation-independent mannose 6-phosphate receptor | NANOMEDSYN; Centre National de la Recherche Scientifique; Universite de Montpellier | 08/14/21 | 2D 3D TSV |
US10894807 | 103 | 102 | HGNC:3788 | PSMA imaging agents | Siemens Medical Solutions USA, Inc. | 08/14/21 | 2D 3D TSV |
US10894794 | 3 | 3 | HGNC:3009 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as antidiabetics | King Abdulaziz University | 08/14/21 | 2D 3D TSV |
US10894786 | 141 | 46 | HGNC:1778 HGNC:1733 | Substituted pyrazole derivatives as selective CDK12/13 inhibitors | Aurigene Discovery Technologies Limited | 08/14/21 | 2D 3D TSV |
US10889546 | 85 | 74 | HGNC:1232 HGNC:14661 | Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof | Jiangsu Hengrui Medicine Co., Ltd. | 08/09/21 | 2D 3D TSV |
US10889610 | 25 | 22 | HGNC:6561 HGNC:6563 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB | 08/09/21 | 2D 3D TSV |
US10889589 | 161 | 157 | HGNC:8031 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | Array BioPharma Inc. | 08/09/21 | 2D 3D TSV |
US10888561 | 14 | 14 | HGNC:9843 | CGRP receptor antagonists | Heptares Therapeutics Limited | 08/09/21 | 2D 3D TSV |
US10889569 | 62 | 32 | HGNC:897 HGNC:895 HGNC:896 | Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 08/09/21 | 2D 3D TSV |
US10889581 | 120 | 40 | HGNC:934 HGNC:2529 HGNC:933 | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use | Amgen Inc. | 08/09/21 | 2D 3D TSV |
US10889552 | 29 | 29 | HGNC:5253 | Dihydroxybenzamide compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | ONCOZEN CO.. LTD. | 08/09/21 | 2D 3D TSV |
US10889568 | 96 | 95 | HGNC:12338 | Inhibitors of TRPC6 | Boehringer Ingelheim International GmbH | 08/09/21 | 2D 3D TSV |
US10888567 | 78 | 78 | HGNC:6059 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | Auckland UniServices Limited | 08/09/21 | 2D 3D TSV |
US10889591 | 69 | 69 | HGNC:8795 | PDE9 inhibitor and use thereof | Nanjing TransThera Biosciences Co. Ltd. | 08/09/21 | 2D 3D TSV |
US10889571 | 217 | 215 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | Terns, Inc. | 08/09/21 | 2D 3D TSV | |
US10889555 | 279 | 268 | Sulfonamide compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 08/09/21 | 2D 3D TSV | |
US10889564 | 52 | 52 | HGNC:2867 | Tetrahydroindazoles and medical uses thereof | Genase Therapeutics B.V. | 08/09/21 | 2D 3D TSV |
US10889579 | 51 | 17 | HGNC:934 HGNC:2529 HGNC:933 | Thiazine derivatives as β-secretase inhibitors and methods of use | Amgen Inc. | 08/09/21 | 2D 3D TSV |
US10889592 | 39 | 21 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. | 08/09/21 | 2D 3D TSV | |
US10889595 | 7 | 7 | HGNC:933 | [1,3]thiazin-2-amine compound, application, and pharmaceutical composition | TETRANOV PHARMACEUTICAL CO., LTD. | 08/09/21 | 2D 3D TSV |
US10888550 | 33 | 33 | HGNC:6819 | Pyrazole derivatives as MALT1 inhibitors | Janssen Pharmaceutica NV | 08/08/21 | 2D 3D TSV |
US10881668 | 12 | 6 | HGNC:13575 HGNC:1105 | Acetamide thienotriazolodiazepines and uses thereof | Dana-Farber Cancer Institute, Inc. | 08/01/21 | 2D 3D TSV |
US10882857 | 17 | 17 | HGNC:3357 | Bicyclic compounds as ATX inhibitors | Hoffmann-La Roche Inc. | 08/01/21 | 2D 3D TSV |
US10882838 | 177 | 61 | HGNC:2160 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY | 08/01/21 | 2D 3D TSV |
US10882844 | 48 | 48 | Compounds useful as immunomodulators | Bristol-Myers Squibb Company | 08/01/21 | 2D 3D TSV | |
US10882835 | 27 | 27 | HGNC:29079 | KDM1A inhibitors for the treatment of disease | Imago Biosciences, Inc. | 08/01/21 | 2D 3D TSV |
US10882859 | 12 | 3 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Kinase inhibitors | TOPIVERT PHARMA LIMITED | 08/01/21 | 2D 3D TSV |
US10882829 | 88 | 22 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pharmaceutical compounds | Sareum Limited | 08/01/21 | 2D 3D TSV |
US10882833 | 17 | 16 | Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof | Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD | 08/01/21 | 2D 3D TSV | |
US10882866 | 148 | 137 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Boehringer Ingelheim International GmbH | 08/01/21 | 2D 3D TSV | |
US10881652 | 2116 | 812 | HGNC:9967 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array Biopharma Inc. | 08/01/21 | 2D 3D TSV |
US10882855 | 56 | 19 | HGNC:3528 HGNC:3529 HGNC:3535 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. | 08/01/21 | 2D 3D TSV |
US10882853 | 12 | 8 | HGNC:6307 HGNC:7029 | Tyrosine kinase inhibitor and application thereof | LaNova Medicines Limited | 08/01/21 | 2D 3D TSV |
US10870635 | 36 | 25 | HGNC:934 HGNC:2529 HGNC:933 | Compounds and their use as BACE1 inhibitors | ALLGENESIS BIOTHERAPEUTICS, INC. | 07/26/21 | 2D 3D TSV |
US10870651 | 52 | 40 | HGNC:3697 HGNC:1780 HGNC:16870 HGNC:1771 HGNC:16627 HGNC:11283 HGNC:9410 HGNC:19007 HGNC:9967 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Dana-Farber Cancer Institute, Inc. | 07/26/21 | 2D 3D TSV |
US10870660 | 278 | 138 | HGNC:3023 HGNC:3024 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. | 07/26/21 | 2D 3D TSV |
US10870641 | 855 | 825 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics, Inc. | 07/26/21 | 2D 3D TSV | |
US10870639 | 27 | 18 | HGNC:3765 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO.. LTD. | 07/26/21 | 2D 3D TSV |
US10870625 | 10 | 10 | HGNC:2861 | Zwitterionic propargyl-linked antifolates useful for treating bacterial infections | UNIVERSITY OF CONNECTICUT | 07/26/21 | 2D 3D TSV |
US10875847 | 13 | 9 | HGNC:6190 HGNC:6192 HGNC:6193 | Aminopyrazoles as selective janus kinase inhibitors | Intervet Inc. | 07/25/21 | 2D 3D TSV |
US10875829 | 6 | 2 | HGNC:11050 HGNC:11048 HGNC:11049 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB | 07/25/21 | 2D 3D TSV |
US10864192 | 4 | 4 | HGNC:108 | Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions | Aristea Translational Medicine Corporation | 07/25/21 | 2D 3D TSV |
US10869871 | 96 | 91 | HGNC:5154 | Compositions and methods of modulating short-chain dehydrogenase activity | CASE WESTERN RESERVE UNIVERSITY; THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 07/25/21 | 2D 3D TSV |
US10874634 | 43 | 23 | HGNC:20581 HGNC:2603 | Compounds and methods for inhibiting CYP26 enzymes | Queen''s University at Kingston | 07/25/21 | 2D 3D TSV |
US10875867 | 202 | 90 | HGNC:8772 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | Boehringer Ingelheim International GmbH | 07/25/21 | 2D 3D TSV |
US10875851 | 183 | 174 | HGNC:3530 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. | 07/25/21 | 2D 3D TSV |
US10875852 | 156 | 151 | HGNC:1133 | Heteroaromatic compounds as BTK inhibitors | Boehringer Ingelheim International GmbH | 07/25/21 | 2D 3D TSV |
US10874687 | 12 | 3 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. | 07/25/21 | 2D 3D TSV | |
US10870618 | 46 | 30 | HGNC:4852 HGNC:4854 HGNC:4853 | Histone deacetylase inhibitors and uses thereof | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 07/25/21 | 2D 3D TSV |
US10874683 | 39 | 26 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | Emory University | 07/25/21 | 2D 3D TSV | |
US10874669 | 32 | 16 | HGNC:3023 HGNC:3024 | Neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY | 07/25/21 | 2D 3D TSV |
US10869929 | 22 | 22 | Phosphonate linkers and their use to facilitate cellular retention of compounds | MERCK SHARP & DOHME CORP. | 07/25/21 | 2D 3D TSV | |
US10874675 | 34 | 34 | HGNC:23357 | Pteridine dione monocarboxylate transporter inhibitors | THE SCRIPPS RESEARCH INSTITUTE | 07/25/21 | 2D 3D TSV |
US10875863 | 26 | 25 | HGNC:10020 | RIPK2 inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK | 07/25/21 | 2D 3D TSV |
US10875864 | 120 | 102 | HGNC:6251 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 07/25/21 | 2D 3D TSV |
US10875832 | 3 | 3 | Substituted pyrimidines for treating bacterial infections | FORGE THERAPEUTICS, INC. | 07/25/21 | 2D 3D TSV | |
US10874640 | 138 | 136 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. | 07/25/21 | 2D 3D TSV | |
US10875854 | 35 | 34 | Triazolopyridines | Hoffmann-La Roche Inc. | 07/25/21 | 2D 3D TSV | |
US10870623 | 23 | 23 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | Hoffmann-La Roche Inc. | 07/25/21 | 2D 3D TSV | |
US10865384 | 119 | 47 | HGNC:2453 HGNC:2452 HGNC:6876 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | Agency for Science, Technology and Research; National University of Singapore | 07/18/21 | 2D 3D TSV |
US10865208 | 231 | 229 | HGNC:16935 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 07/18/21 | 2D 3D TSV |
US10864248 | 3 | 3 | Dab2 inhibitors for the prevention and treatment of cystic fibrosis | TRUSTEES OF DARTMOUTH COLLEGE | 07/18/21 | 2D 3D TSV | |
US10865182 | 17 | 17 | Difluoroketamide derivatives as HtrA1 inhibitors | Hoffmann-La Roche Inc. | 07/18/21 | 2D 3D TSV | |
US10864201 | 57 | 57 | Heteroaromatic compounds as Vanin inhibitors | Boehringer Ingelheim International GmbH | 07/18/21 | 2D 3D TSV | |
US10865206 | 15 | 15 | HGNC:1778 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Syros Pharmaceuticals, Inc. | 07/18/21 | 2D 3D TSV |
US10864202 | 75 | 75 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research, Inc. | 07/18/21 | 2D 3D TSV |
US10865186 | 25 | 12 | HGNC:8154 HGNC:8156 | Opioid agonists and uses thereof | Nektar Therapeutics | 07/18/21 | 2D 3D TSV |
US10865195 | 7 | 7 | HGNC:10548 | Pet imaging agents | Novartis AG | 07/18/21 | 2D 3D TSV |
US10851050 | 39 | 39 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY | 07/13/21 | 2D 3D TSV | |
US10849881 | 117 | 116 | HGNC:10548 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | Hoffmann-La Roche Inc. | 07/13/21 | 2D 3D TSV |
US10849901 | 159 | 140 | Arf6 inhibitors and methods of synthesis and use thereof | Navigen, Inc.; The University of Utah Research Foundation | 07/12/21 | 2D 3D TSV | |
US10851083 | 186 | 185 | Benzoimidazoles as prolyl hydroxylase inhibitors | Janssen Pharmaceutica NV | 07/12/21 | 2D 3D TSV | |
US10849883 | 380 | 377 | HGNC:2771 | Benzopyrazole compounds and analogues thereof | BioCryst Pharmaceuticals, Inc. | 07/12/21 | 2D 3D TSV |
US10851091 | 62 | 21 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Benzoxazepin oxazolidinone compounds and methods of use | Genentech, Inc. | 07/12/21 | 2D 3D TSV |
US10851116 | 188 | 43 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Bicyclic amines as novel JAK kinase inhibitors | LEO Pharma A/S | 07/12/21 | 2D 3D TSV |
US10851105 | 96 | 12 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 07/12/21 | 2D 3D TSV |
US10849982 | 64 | 64 | HGNC:2717 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 Therapeutics, Inc. | 07/12/21 | 2D 3D TSV |
US10851110 | 95 | 92 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 07/12/21 | 2D 3D TSV | |
US10851102 | 162 | 52 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | Theravance Biopharma R&D IP, LLC | 07/12/21 | 2D 3D TSV |
US10851089 | 32 | 30 | HGNC:7158 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | Foresee Pharmaceuticals Co., Ltd. | 07/12/21 | 2D 3D TSV |
US10851080 | 31 | 31 | HGNC:8031 | Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds | Array Biopharma Inc. | 07/12/21 | 2D 3D TSV |
US10851092 | 6 | 3 | HGNC:9967 | Pyridine compound | Daiichi Sankyo Company, Limited | 07/12/21 | 2D 3D TSV |
US10851082 | 434 | 227 | HGNC:7110 HGNC:7111 | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) | Northwestern University | 07/12/21 | 2D 3D TSV |
US10851108 | 7 | 7 | HGNC:6255 | Substituted bicyclic heterocyclic compounds | Bristol-Myers Squibb Company | 07/12/21 | 2D 3D TSV |
US10849898 | 122 | 118 | HGNC:29079 | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. | 07/12/21 | 2D 3D TSV |
US10858342 | 226 | 112 | HGNC:2592 HGNC:2591 | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases | Boehringer Ingelheim International GmbH | 07/11/21 | 2D 3D TSV |
US10857082 | 27 | 26 | Diarylalkanes as potent inhibitors of binuclear enzymes | Unigen, Inc. | 07/11/21 | 2D 3D TSV | |
US10858323 | 12 | 3 | HGNC:4852 HGNC:14064 HGNC:4854 HGNC:4853 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC | 07/11/21 | 2D 3D TSV |
US10858359 | 6 | 6 | HGNC:9644 | Heterocyclic ring derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. | 07/11/21 | 2D 3D TSV |
US10858373 | 106 | 53 | HGNC:17038 | Heterocyclic spiro compounds as MAGL inhibitors | Pfizer Inc. | 07/11/21 | 2D 3D TSV |
US10858344 | 20 | 20 | HGNC:3078 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 Therapeutics (NI) Limited | 07/11/21 | 2D 3D TSV |
US10858364 | 15 | 3 | HGNC:3432 HGNC:3430 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:11719 HGNC:12434 HGNC:3236 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | Acerta Pharma B.V. | 07/11/21 | 2D 3D TSV |
US10858362 | 311 | 111 | HGNC:8775 HGNC:8774 HGNC:8776 | Imidazopyrazinones as PDE1 inhibitors | H. Lundbeck A/S | 07/11/21 | 2D 3D TSV |
US10858355 | 37 | 34 | HGNC:8978 | Inhibitors of phosphatidylinositol 3-kinase gamma | AstraZeneca AB | 07/11/21 | 2D 3D TSV |
US10858368 | 22 | 22 | HGNC:5302 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION; PRAEVENTIX, LLC | 07/11/21 | 2D 3D TSV |
US10858326 | 5 | 5 | HGNC:17734 | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof | PURDUE PHARMA L.P. | 07/11/21 | 2D 3D TSV |
US10858356 | 80 | 80 | HGNC:4324 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | Chugai Seiyaku Kabushiki Kaisha | 07/11/21 | 2D 3D TSV |
US10858316 | 146 | 98 | HGNC:6943 | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof | UNIVERSITY OF MARYLAND, BALTIMORE | 07/11/21 | 2D 3D TSV |
US10858365 | 518 | 119 | HGNC:268 HGNC:262 HGNC:263 HGNC:264 | Triazolo-pyrimidine compounds and uses thereof | TBA | 07/11/21 | 2D 3D TSV |
US10858366 | 71 | 41 | Tricyclic compounds useful to treat orthomyxovirus infections | Novartis AG | 07/11/21 | 2D 3D TSV | |
US10844038 | 134 | 16 | HGNC:11283 HGNC:8980 HGNC:8979 HGNC:6877 HGNC:8978 HGNC:6735 HGNC:4037 HGNC:6871 HGNC:3942 HGNC:8977 HGNC:9967 HGNC:3765 HGNC:6171 HGNC:11393 HGNC:12841 HGNC:9617 HGNC:3432 HGNC:6844 HGNC:4840 HGNC:3697 HGNC:6845 HGNC:1079 HGNC:6846 HGNC:1057 HGNC:1133 HGNC:6847 HGNC:16627 HGNC:1097 HGNC:6342 HGNC:3955 HGNC:6840 HGNC:2444 HGNC:6842 HGNC:6524 HGNC:6843 | 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions | SABILA BIOSCIENCES LLC | 07/06/21 | 2D 3D TSV |
US10844056 | 73 | 63 | HGNC:5253 | Fused amino pyridine as HSP90 inhibitors | Curis, Inc. | 07/06/21 | 2D 3D TSV |
US10844067 | 255 | 86 | HGNC:6307 HGNC:9967 | Heterocyclic compounds as RET kinase inhibitors | Cancer Research Technology Limited | 07/06/21 | 2D 3D TSV |
US10842803 | 100 | 100 | HGNC:11491 | Imidazopyridines Syk inhibitors | KRONOS BIO, INC. | 07/06/21 | 2D 3D TSV |
US10844057 | 52 | 13 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Process for preparing JAK inhibitors and intermediates thereof | Theravance Biopharma R&D IP, LLC | 07/06/21 | 2D 3D TSV |
US10844062 | 94 | 92 | HGNC:6307 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | Incheon University Industry Academic Cooperation Foundation; Samjin Pharmaceutical Co., Ltd.; Bamichem Co., Ltd. | 07/06/21 | 2D 3D TSV |
US10844069 | 438 | 146 | HGNC:7027 HGNC:12446 | Pyrrolotriazine compounds as TAM inhibitors | Incyte Corporation | 07/06/21 | 2D 3D TSV |
US10842799 | 110 | 107 | HGNC:6871 | Serine/threonine kinase inhibitors | GENENTECH, INC. | 07/06/21 | 2D 3D TSV |
US10844032 | 286 | 271 | HGNC:990 | Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors | Vanderbilt University | 07/06/21 | 2D 3D TSV |
US10844077 | 44 | 22 | HGNC:4840 HGNC:1133 | Thiazolyl-containing compounds for treating proliferative diseases | Dana-Farber Cancer Institute, Inc. | 07/06/21 | 2D 3D TSV |
US10844044 | 364 | 359 | HGNC:12757 | WDR5 inhibitors and modulators | Vanderbilt University | 07/06/21 | 2D 3D TSV |
US10836763 | 48 | 12 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | 5 to 7 membered heterocyclic amides as JAK inhibitors | Theravance Biopharma R&D IP, LLC | 06/30/21 | 2D 3D TSV |
US10836764 | 164 | 55 | HGNC:5295 HGNC:5294 | 5-HT2C receptor agonists and compositions and methods of use | Arena Pharmaceuticals, Inc. | 06/30/21 | 2D 3D TSV |
US10836773 | 6 | 6 | HGNC:7056 | 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds | Eli Lilly and Company | 06/30/21 | 2D 3D TSV |
US10836758 | 75 | 73 | HGNC:10597 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 06/30/21 | 2D 3D TSV |
US10829489 | 98 | 57 | HGNC:8810 | Bicyclic heterocyclic derivatives | Merck Patent GmbH | 06/30/21 | 2D 3D TSV |
US10836743 | 110 | 58 | HGNC:6833 HGNC:6834 HGNC:29079 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 06/30/21 | 2D 3D TSV |
US10836720 | 24 | 13 | HGNC:6153 | Inhibitors of integrin alpha 5 beta 1 and methods of use | The Regents of the University of California | 06/30/21 | 2D 3D TSV |
US10836768 | 205 | 47 | HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Ogeda SA | 06/30/21 | 2D 3D TSV |
US10836742 | 15 | 15 | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals | Neomed Institute | 06/30/21 | 2D 3D TSV | |
US10836741 | 13 | 12 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | Valo Early Discovery, Inc. | 06/30/21 | 2D 3D TSV | |
US10836728 | 22 | 11 | HGNC:711 HGNC:8156 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | Mebias Discovery, Inc. | 06/30/21 | 2D 3D TSV |
US10836769 | 56 | 55 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. | 06/30/21 | 2D 3D TSV | |
US10835536 | 52 | 50 | HGNC:3689 | Therapeutic agent for FGFR inhibitor-resistant cancer | Taiho Pharmaceutical Co., Ltd. | 06/30/21 | 2D 3D TSV |
US10829488 | 46 | 22 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 06/29/21 | 2D 3D TSV | |
US10828301 | 51 | 51 | HGNC:11491 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. | 06/28/21 | 2D 3D TSV |
US10829480 | 296 | 153 | HGNC:8155 HGNC:8156 | 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives | GRUENENTHAL GMBH | 06/28/21 | 2D 3D TSV |
US10829478 | 698 | 150 | HGNC:7160 HGNC:195 HGNC:7159 HGNC:220 HGNC:221 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV | 06/28/21 | 2D 3D TSV |
US10829492 | 73 | 50 | HGNC:6192 HGNC:8031 HGNC:8032 HGNC:8033 | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; CENTAURUS BIOPHARMA CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. | 06/28/21 | 2D 3D TSV |
US10829446 | 156 | 155 | Aryl sulfonohydrazides | MONASH UNIVERSITY; The Walter and Eliza Hall Institute of Medical Research | 06/28/21 | 2D 3D TSV | |
US10829481 | 189 | 189 | Benzimidazole derivatives as modulators of ROR-gamma | Vitae Pharmaceuticals, LLC | 06/28/21 | 2D 3D TSV | |
US10829487 | 150 | 149 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | Boehringer Ingelheim International GmbH | 06/28/21 | 2D 3D TSV | |
US10829493 | 69 | 23 | HGNC:6342 | Compositions and methods for treating KIT- and PDGFRA-mediated diseases | Blueprint Medicines Corporation | 06/28/21 | 2D 3D TSV |
US10828299 | 7 | 7 | HGNC:11491 | Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | KRONOS BIO, INC. | 06/28/21 | 2D 3D TSV |
US10829438 | 7 | 7 | Neprilysin inhibitors | Theravance Biopharma R&D IP, LLC | 06/28/21 | 2D 3D TSV | |
US10829500 | 5 | 5 | HGNC:933 | Pyridyl-triazabicycles | Hoffmann-La Roche Inc. | 06/28/21 | 2D 3D TSV |
US10829502 | 125 | 82 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Pyrimidinones as PI3K inhibitors | Incyte Corporation; Incyte Holdings Corporation | 06/28/21 | 2D 3D TSV |
US10829491 | 22 | 22 | HGNC:1133 | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD | 06/28/21 | 2D 3D TSV |
US10828300 | 248 | 244 | HGNC:1133 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | Celgene CAR LLC | 06/28/21 | 2D 3D TSV |
US10829448 | 121 | 111 | Substituted benzoimidazoles as modulators of ROR-γ | Vitae Pharmaceuticals, LLC | 06/28/21 | 2D 3D TSV | |
US10829490 | 71 | 9 | HGNC:1780 HGNC:1771 HGNC:1777 HGNC:1774 HGNC:1773 HGNC:1775 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. | 06/28/21 | 2D 3D TSV |
US10828290 | 327 | 108 | HGNC:19310 HGNC:8987 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | Incyte Corporation; Incyte Holdings Corporation | 06/28/21 | 2D 3D TSV |
US10829496 | 29 | 27 | HGNC:17967 | Thienopyridines and benzothiophenes useful as IRAK4 inhibitors | Bristol-Myers Squibb Company | 06/28/21 | 2D 3D TSV |
US10829483 | 103 | 103 | HGNC:17989 | Thiophene, manufacturing method thereof, and pharmaceutical application of same | CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD.; CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.; CSTONE PHARMACEUTICALS | 06/28/21 | 2D 3D TSV |
US10822352 | 718 | 703 | HGNC:2771 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. | 06/21/21 | 2D 3D TSV |
US10822319 | 2 | 2 | Crystal of DPP-IV long-acting inhibitor and salt | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.; CENTAURUS BIOPHARMA CO., LTD. | 06/21/21 | 2D 3D TSV | |
US10822334 | 60 | 30 | HGNC:3430 HGNC:3236 | ErbB receptor inhibitors | TBA | 06/21/21 | 2D 3D TSV |
US10822348 | 937 | 789 | Inhibitors of Bruton's tyrosine kinase and methods of their use | Janssen Pharmaceutica NV | 06/21/21 | 2D 3D TSV | |
US10822345 | 64 | 63 | HGNC:6221 | KV1.3 inhibitors and their medical application | 4SC AG | 06/21/21 | 2D 3D TSV |
US10822331 | 4 | 1 | HGNC:882 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 06/21/21 | 2D 3D TSV |
US10822341 | 148 | 37 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | Pfizer Inc. | 06/21/21 | 2D 3D TSV |
US10822342 | 12 | 12 | HGNC:6853 | Pyrazolopyrimidine derivatives as NIK inhibitors | Janssen Pharmaceutica NV | 06/21/21 | 2D 3D TSV |
US10822338 | 75 | 74 | HGNC:263 | Substituted aminoquinazoline compounds as A2A antagonist | Merck Sharp & Dohme Corp. | 06/21/21 | 2D 3D TSV |
US10821115 | 969 | 797 | Compounds that inhibit Mcl-1 protein | AMGEN INC. | 06/20/21 | 2D 3D TSV | |
US10815234 | 116 | 115 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. | 06/14/21 | 2D 3D TSV | |
US10815244 | 10 | 10 | HGNC:3236 | Isoidide derivatives and methods of making and using same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 06/14/21 | 2D 3D TSV |
US10815241 | 10 | 10 | HGNC:7010 | Optically active azabicyclo ring derivative | Sumitomo Dainippon Pharma Co., Ltd. | 06/14/21 | 2D 3D TSV |
US10813932 | 120 | 31 | HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:20790 HGNC:6874 HGNC:6876 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors | Respivert Limited | 06/13/21 | 2D 3D TSV |
US10815215 | 268 | 215 | HGNC:2867 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGELLSCHAFT; THE BROAD INSTITUTE, INC.; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE GENERAL HOSPITAL CORPORATION | 06/13/21 | 2D 3D TSV |
US10815229 | 1146 | 325 | HGNC:10593 HGNC:10585 HGNC:10596 | Benzenesulfonamide compounds and their use as therapeutic agents | Xenon Pharmaceuticals Inc. | 06/13/21 | 2D 3D TSV |
US10815213 | 190 | 140 | HGNC:1133 HGNC:3236 | Bruton's tyrosine kinase inhibitors | Pfizer Inc. | 06/13/21 | 2D 3D TSV |
US10815208 | 4 | 4 | Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative | Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD | 06/13/21 | 2D 3D TSV | |
US10815206 | 95 | 90 | RIP1 inhibitory compounds and methods for making and using the same | Rigel Pharmaceuticals, Inc. | 06/13/21 | 2D 3D TSV | |
US10813930 | 107 | 107 | HGNC:3690 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | Incyte Corporation; Incyte Holdings Corporation | 06/13/21 | 2D 3D TSV |
US10813942 | 17 | 17 | HGNC:742 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | Pfizer Inc. | 06/13/21 | 2D 3D TSV |
US10806718 | 605 | 192 | HGNC:8775 HGNC:8774 HGNC:8776 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. Lundbeck A/S | 06/11/21 | 2D 3D TSV |
US10807988 | 693 | 382 | HGNC:8155 HGNC:8156 | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | Grünenthal GmbH | 06/11/21 | 2D 3D TSV |
US10807989 | 571 | 289 | HGNC:8155 HGNC:8156 | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | GRÜNENTHAL GMBH | 06/11/21 | 2D 3D TSV |
US10807982 | 105 | 104 | HGNC:13575 | Bromodomain inhibitors | Celgene Quanticel Research, Inc. | 06/11/21 | 2D 3D TSV |
US10806724 | 59 | 59 | HGNC:4594 | Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use | Merck Sharp & Dohme Corp. | 06/11/21 | 2D 3D TSV |
US10807985 | 169 | 124 | Compositions useful for treating disorders related to kit | Blueprint Medicines Corporation | 06/11/21 | 2D 3D TSV | |
US10807952 | 101 | 101 | HGNC:2771 | Compounds for treatment of immune inflammatory disorders | Achillion Pharmaceuticals, Inc. | 06/11/21 | 2D 3D TSV |
US10807993 | 63 | 51 | HGNC:6251 | Dihydrochromene derivatives | Sumitomo Dainippon Pharma Co., Ltd. | 06/11/21 | 2D 3D TSV |
US10807980 | 220 | 156 | Dihydropyrrolopyridine inhibitors of ROR-gamma | Vitae Pharmaceuticals, LLC | 06/11/21 | 2D 3D TSV | |
US10807986 | 522 | 200 | HGNC:9967 | Fused pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 06/11/21 | 2D 3D TSV |
US10807944 | 144 | 42 | HGNC:4852 HGNC:14064 HGNC:13315 HGNC:4854 HGNC:4853 | HDAC inhibitor compounds and methods of treatment | University of Florida Research Foundation, Inc.; The Scripps Research Institute | 06/11/21 | 2D 3D TSV |
US10807994 | 99 | 97 | HGNC:12761 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. | 06/11/21 | 2D 3D TSV |
US10807966 | 27 | 16 | HGNC:10251 HGNC:10252 | Heterocyclic compounds as kinase inhibitors | Translational Drug Development, LLC | 06/11/21 | 2D 3D TSV |
US10807956 | 210 | 101 | HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. | 06/11/21 | 2D 3D TSV |
US10806785 | 205 | 191 | Immunomodulator compounds and methods of use | Incyte Corporation | 06/11/21 | 2D 3D TSV | |
US10807974 | 309 | 161 | HGNC:6833 HGNC:6834 HGNC:80 HGNC:6666 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | The Institute of Cancer Research: Royal Cancer Hospital | 06/11/21 | 2D 3D TSV |
US10806794 | 28 | 28 | Protease inhibitors having enhanced features | Nektar Therapeutics | 06/11/21 | 2D 3D TSV | |
US10807971 | 68 | 17 | HGNC:16672 HGNC:3009 | Pyrrolidinone compounds | Eli Lilly and Company | 06/11/21 | 2D 3D TSV |
US10806720 | 76 | 51 | HGNC:644 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | University of Tennessee Research Foundation | 06/11/21 | 2D 3D TSV |
US10807991 | 122 | 42 | HGNC:3167 HGNC:3165 HGNC:14299 | Spiro-cyclic amine derivatives as S1P modulators | AbbVie B.V.; AbbVie, Inc. | 06/11/21 | 2D 3D TSV |
US10807959 | 266 | 260 | HGNC:12757 | WDR5-MLL1 inhibitors and modulators | Vanderbilt University | 06/11/21 | 2D 3D TSV |
US10800755 | 217 | 38 | HGNC:3023 HGNC:5286 HGNC:6251 | 2,6-disubstituted pyridine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. | 06/01/21 | 2D 3D TSV |
US10800739 | 37 | 20 | HGNC:270 HGNC:272 | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. | 06/01/21 | 2D 3D TSV |
US10799507 | 607 | 155 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors | Leo Pharma A/S | 06/01/21 | 2D 3D TSV |
US10800725 | 60 | 20 | Arylpropionyl-triketone antibacterial agents | TBA | 06/01/21 | 2D 3D TSV | |
US10800778 | 120 | 40 | Beta-lactamase inhibitor compounds | Entasis Therapeutics Limited | 06/01/21 | 2D 3D TSV | |
US10800786 | 33 | 32 | HGNC:10548 | Bicyclic compounds as ATX inhibitors | Hoffman-La Roche Inc. | 06/01/21 | 2D 3D TSV |
US10800783 | 433 | 218 | HGNC:1771 | CDK2/4/6 inhibitors | Pfizer Inc. | 06/01/21 | 2D 3D TSV |
US10800761 | 113 | 105 | HGNC:6863 | Carboxamide compounds and uses thereof | Incyte Corporation | 06/01/21 | 2D 3D TSV |
US10799494 | 22 | 22 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | TBA | 06/01/21 | 2D 3D TSV | |
US10799605 | 13 | 7 | HGNC:8039 | Conjugate comprising a neurotensin receptor ligand and use thereof | 3B Pharmaceuticals GMBH | 06/01/21 | 2D 3D TSV |
US10800776 | 45 | 25 | HGNC:4594 HGNC:6251 | Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 06/01/21 | 2D 3D TSV |
US10800779 | 138 | 138 | HGNC:29079 | Heterocyclic compounds as LSD1 inhibitors | Incyte Corporation | 06/01/21 | 2D 3D TSV |
US10800768 | 271 | 266 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 06/01/21 | 2D 3D TSV | |
US10800769 | 265 | 122 | HGNC:1925 | Heterocyclic inhibitors of ATR kinase | Board of Regents, The University of Texas System; ChemPartner Corporation | 06/01/21 | 2D 3D TSV |
US10800774 | 64 | 32 | HGNC:1925 | Heterocyclic inhibitors of ATR kinase | Board of Regents, The University of Texas System; ChemPartner Corporation | 06/01/21 | 2D 3D TSV |
US10800804 | 26 | 12 | HGNC:6561 HGNC:6563 | Hybrid galactoside inhibitor of galectins | TBA | 06/01/21 | 2D 3D TSV |
US10800744 | 41 | 41 | HGNC:3827 | Imidazole derivatives as formyl peptide receptor modulators | ALLERGAN, INC. | 06/01/21 | 2D 3D TSV |
US10800765 | 63 | 62 | HGNC:4502 | Indole derivative used as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. | 06/01/21 | 2D 3D TSV |
US10800792 | 937 | 912 | HGNC:1133 | Inhibitors of Bruton's tyrosine kinase and method of their use | Janssen Pharmaceutica NV | 06/01/21 | 2D 3D TSV |
US10800757 | 96 | 94 | HGNC:12338 | Inhibitors of TRPC6 | Boehringer Ingelheim International GmbH; Hydra Biosciences, LLC | 06/01/21 | 2D 3D TSV |
USRE48253 | 9 | 9 | HGNC:12576 | Methotrexate adjuvants to reduce toxicity and methods for using the same | Tosk, Inc. | 06/01/21 | 2D 3D TSV |
US10800784 | 246 | 123 | HGNC:8809 HGNC:8810 | Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof | JAPAN TOBACCO INC. | 06/01/21 | 2D 3D TSV |
US10800746 | 22 | 11 | HGNC:897 HGNC:895 | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT | 06/01/21 | 2D 3D TSV |
US10800775 | 14 | 7 | HGNC:6190 | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same | ACLARIS THERAPEUTICS, INC. | 06/01/21 | 2D 3D TSV |
US10800764 | 23 | 6 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | Janssen Pharmaceutica NV | 06/01/21 | 2D 3D TSV | |
US10800785 | 97 | 85 | HGNC:1133 | Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors | Shanghai Fochon Pharmaceutical Co., Ltd.; Fochon Pharmaceuticals, Ltd. | 06/01/21 | 2D 3D TSV |
US10800753 | 7 | 7 | HGNC:23 | Tetrahydrothiophene-based GABA aminotransferase inactivators and analogs thereof for treating neurological disorders | Northwestern University | 06/01/21 | 2D 3D TSV |
US10800767 | 82 | 36 | HGNC:11799 HGNC:11796 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. | 06/01/21 | 2D 3D TSV |
US10799518 | 188 | 179 | HGNC:3827 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | ALLERGAN, INC. | 06/01/21 | 2D 3D TSV |
US10793561 | 2 | 2 | HGNC:262 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. | 05/14/21 | 2D 3D TSV |
US10793528 | 143 | 73 | HGNC:8156 | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | GRÜNENTHAL GMBH | 05/14/21 | 2D 3D TSV |
US10793556 | 178 | 34 | HGNC:8155 HGNC:8156 | 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | GRUENENTHAL GMBH | 05/14/21 | 2D 3D TSV |
US10793564 | 145 | 144 | HGNC:6161 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. | 05/14/21 | 2D 3D TSV |
US10793552 | 3 | 3 | HGNC:550 | Amino pyrimidine ssao inhibitors | ELI LILLY AND COMPANY | 05/14/21 | 2D 3D TSV |
US10793582 | 85 | 84 | HGNC:17929 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION | 05/14/21 | 2D 3D TSV |
US10793567 | 30 | 15 | HGNC:4852 HGNC:4853 | Bicyclic inhibitors of histone deacetylase | Rodin Therapeutics, Inc. | 05/14/21 | 2D 3D TSV |
US10793579 | 370 | 361 | HGNC:17967 | Bicyclic-fused heteroaryl or aryl compounds | Pfizer Inc. | 05/14/21 | 2D 3D TSV |
US10793566 | 134 | 123 | HGNC:6735 HGNC:1057 HGNC:1133 HGNC:3236 HGNC:6524 | Bruton's tyrosine kinase inhibitors | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 05/14/21 | 2D 3D TSV |
US10793576 | 128 | 126 | HGNC:1133 | Compound used as Bruton's tyrosine kinase inhibitor and preparation method and application thereof | CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD.; CHENGDU HIGHBRED PHARMACEUTICAL CO., LTD. | 05/14/21 | 2D 3D TSV |
US10793563 | 532 | 502 | HGNC:19687 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH; VERTEX PHARMACEUTICALS INCORPORATED | 05/14/21 | 2D 3D TSV |
US10793514 | 38 | 19 | HGNC:10943 | Glutamine transport inhibitors and methods for treating cancer | Vanderbilt University | 05/14/21 | 2D 3D TSV |
US10793565 | 4 | 4 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 05/14/21 | 2D 3D TSV | |
US10793535 | 51 | 45 | Heterocyclic glutaminase inhibitors | Calithera Biosciences, Inc. | 05/14/21 | 2D 3D TSV | |
US10793568 | 340 | 336 | HGNC:7967 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. | 05/14/21 | 2D 3D TSV |
US10793575 | 89 | 59 | HGNC:1133 | Oxoisoquinoline derivatives | CARNA BIOSCIENCES, INC. | 05/14/21 | 2D 3D TSV |
US10792283 | 7 | 7 | HGNC:8977 | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors | HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD. | 05/14/21 | 2D 3D TSV |
US10793545 | 22 | 22 | HGNC:17967 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | Bayer Pharma Aktiengesellschaft | 05/14/21 | 2D 3D TSV |
US10793591 | 16 | 15 | Substituted nucleosides, nucleotides and analogs thereof | Janssen BioPharma, Inc. | 05/14/21 | 2D 3D TSV | |
US10793580 | 310 | 310 | HGNC:8783 | Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors | LEO Pharma A/S | 05/14/21 | 2D 3D TSV |
US10793529 | 4 | 4 | HGNC:9602 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. | 05/14/21 | 2D 3D TSV |
US10793549 | 63 | 59 | Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.; YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. | 05/14/21 | 2D 3D TSV | |
US10793574 | 218 | 217 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 05/14/21 | 2D 3D TSV | |
US10787452 | 579 | 555 | HGNC:882 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED | 05/11/21 | 2D 3D TSV |
US10787435 | 57 | 56 | HGNC:6857 | ASK1 inhibitor and preparation method and use thereof | Fuijan Cosunter Pharmaceutical Co. Ltd. | 05/09/21 | 2D 3D TSV |
US10787434 | 9 | 9 | HGNC:10894 | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY, LTD | 05/09/21 | 2D 3D TSV |
US10787459 | 13 | 3 | HGNC:10548 | Bicyclic compounds as ATX inhibitors | Hoffmann-La Roche Inc. | 05/09/21 | 2D 3D TSV |
US10787419 | 92 | 90 | Cannabinoid receptor mediating iminopyrazole compounds | The United States of America, as represented by the Secretary, Department of Health and Human Services | 05/09/21 | 2D 3D TSV | |
US10787457 | 78 | 78 | HGNC:9967 | Fused pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 05/09/21 | 2D 3D TSV |
US10787436 | 82 | 40 | HGNC:1780 HGNC:1771 HGNC:1778 HGNC:6881 HGNC:1722 HGNC:6112 HGNC:6850 HGNC:1779 HGNC:1774 HGNC:6886 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Dana-Farber Cancer Institute, Inc. | 05/09/21 | 2D 3D TSV |
US10787453 | 2 | 2 | HGNC:9922 | Octahydropyrrolopyrroles their preparation and use | The Trustees of Columbia University in the City of New York | 05/09/21 | 2D 3D TSV |
US10787472 | 23 | 23 | HGNC:10582 | Prodrugs of pyridone amides useful as modulators of sodium channels | Vertex Pharmaceuticals Incorporated | 05/09/21 | 2D 3D TSV |
US10787450 | 255 | 253 | HGNC:10252 | Spiro-fused cyclic ureas as inhibitors of rock | Bristol-Myers Squibb Company | 05/09/21 | 2D 3D TSV |
US10787438 | 40 | 18 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | Pfizer Inc. | 05/09/21 | 2D 3D TSV | |
US10787425 | 105 | 105 | HGNC:5154 | Thiazolidinedione derivative and use thereof | INDUSTRY-ACADEMIC COOPERATION FOUNDATION CHOSUN UNIVERSITY | 05/09/21 | 2D 3D TSV |
US10781209 | 196 | 93 | HGNC:13575 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins | Incyte Corporation | 05/03/21 | 2D 3D TSV |
US10781212 | 4 | 2 | 2,6-diamino pyridine compounds | Eli Lilly and Company | 05/03/21 | 2D 3D TSV | |
US10781180 | 4 | 4 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. | 05/03/21 | 2D 3D TSV | |
US10781202 | 10 | 10 | HGNC:8781 | Azetidinyloxyphenylpyrrolidine compounds | Eli Lilly and Company | 05/03/21 | 2D 3D TSV |
US10781182 | 12 | 6 | HGNC:7463 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. | 05/03/21 | 2D 3D TSV |
US10781185 | 149 | 108 | HGNC:17270 | Heterocyclic compounds for the inhibition of PASK | BioEnergenix LLC | 05/03/21 | 2D 3D TSV |
US10781181 | 216 | 108 | HGNC:6371 HGNC:6357 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED | 05/03/21 | 2D 3D TSV |
US10781211 | 677 | 260 | HGNC:17038 | Spirocycle compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 05/03/21 | 2D 3D TSV |
US10781204 | 378 | 163 | HGNC:6192 HGNC:12440 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 05/03/21 | 2D 3D TSV |
US10781200 | 140 | 137 | HGNC:6371 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. | 05/03/21 | 2D 3D TSV |
US10780095 | 30 | 25 | HGNC:15836 | Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 05/02/21 | 2D 3D TSV |
US10780092 | 156 | 151 | HGNC:4685 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | Merck Sharp & Dohme Corp. | 05/02/21 | 2D 3D TSV |
US10780090 | 537 | 352 | HGNC:30660 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | Millennium Pharmaceuticals, Inc. | 05/02/21 | 2D 3D TSV |
US10780082 | 18 | 3 | HGNC:427 | Macrocycle and composition comprising thereof | Shenzhen TargetRx, Inc. | 05/02/21 | 2D 3D TSV |
US10780078 | 21 | 7 | HGNC:8153 HGNC:8155 HGNC:8156 | Mu opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; FRIEDRICH-ALEXANDER-UNIVERSITÄT; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 05/02/21 | 2D 3D TSV |
US10781171 | 288 | 287 | HGNC:4501 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | Epics Therapeutics | 05/02/21 | 2D 3D TSV |
US10766893 | 768 | 242 | HGNC:8775 HGNC:8774 HGNC:8776 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. Lundbeck A/S | 04/26/21 | 2D 3D TSV |
US10766881 | 246 | 83 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | Array Biopharma Inc. | 04/26/21 | 2D 3D TSV | |
US10766883 | 18 | 9 | HGNC:6190 HGNC:6192 | Aminopyrazoles as janus kinase inhibitors | Merck Sharp & Dohme Corp. | 04/26/21 | 2D 3D TSV |
US10766894 | 52 | 13 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Aza-indazole compounds for use in tendon and/or ligament injuries | NOVARTIS AG | 04/26/21 | 2D 3D TSV |
US10766884 | 294 | 137 | HGNC:1773 | Cyclin dependent kinase inhibitors | Pfizer Inc. | 04/26/21 | 2D 3D TSV |
US10766897 | 213 | 155 | HGNC:6251 HGNC:550 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC | 04/26/21 | 2D 3D TSV |
US10766864 | 106 | 106 | HGNC:8156 | Morphinan derivatives for the treatment of neuropathic pain | Nektar Therapeutics | 04/26/21 | 2D 3D TSV |
US10766903 | 245 | 243 | HGNC:12630 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | ALMAC DISCOVERY LIMITED | 04/26/21 | 2D 3D TSV |
US10766858 | 25 | 19 | HGNC:10597 | Substituted benzamides and methods of use thereof | GENENTECH, INC.; XENON PHARMACEUTICALS INC. | 04/26/21 | 2D 3D TSV |
US10766878 | 63 | 33 | HGNC:497 | Sulfonylcycloalkyl carboxamide compounds | Genentech, Inc. | 04/26/21 | 2D 3D TSV |
US10765676 | 43 | 43 | HGNC:8031 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. | 04/26/21 | 2D 3D TSV |
US10766902 | 96 | 96 | HGNC:12761 | Wee-1 inhibiting pyrazolopyrimidinone compounds | ALMAC DISCOVERY LIMITED | 04/26/21 | 2D 3D TSV |
US10774065 | 22 | 22 | HGNC:9644 | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | NOVARTIS AG | 04/25/21 | 2D 3D TSV |
US10772893 | 488 | 432 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT | 04/25/21 | 2D 3D TSV | |
US10774070 | 79 | 39 | HGNC:9967 | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors | BLUEPRINT MEDICINES CORPORATION | 04/25/21 | 2D 3D TSV |
US10774051 | 1232 | 1204 | HGNC:8537 | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. | 04/25/21 | 2D 3D TSV |
US10774068 | 200 | 123 | HGNC:11408 HGNC:11406 | Composition and methods for inhibiting mammalian sterile 20-like kinase 1 | THE SCRIPPS RESEARCH INSTITUTE; UNIVERSITÄT BREMEN | 04/25/21 | 2D 3D TSV |
US10774069 | 4 | 3 | HGNC:6666 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | PHARMAKEA, INC. | 04/25/21 | 2D 3D TSV |
US10774054 | 16 | 8 | HGNC:7967 | FXR (NR1H4) modulating compounds | Gilead Sciences, Inc. | 04/25/21 | 2D 3D TSV |
US10774102 | 106 | 106 | HGNC:6563 | Galactoside inhibitor of galectins | Galecto Biotech AB | 04/25/21 | 2D 3D TSV |
US10774053 | 706 | 352 | HIV protease inhibitors | Gilead Sciences, Inc. | 04/25/21 | 2D 3D TSV | |
US10774052 | 194 | 191 | HGNC:3691 | Heteroaryl compounds and uses thereof | Celgene CAR LLC; Sanofi | 04/25/21 | 2D 3D TSV |
US10752635 | 54 | 54 | HGNC:6863 | Indazole compounds and uses thereof | Incyte Corporation | 04/25/21 | 2D 3D TSV |
US10774063 | 26 | 24 | HGNC:10289 | Materials and method for inhibiting replication protein A and uses thereof | Indiana University Research and Technology Corporation | 04/25/21 | 2D 3D TSV |
US10774085 | 105 | 105 | HGNC:8031 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | ARRAY BIOPHARMA INC. | 04/25/21 | 2D 3D TSV |
US10774071 | 762 | 381 | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. | 04/25/21 | 2D 3D TSV | |
US10774056 | 197 | 71 | HGNC:4852 HGNC:6251 HGNC:4854 HGNC:4853 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. | 04/25/21 | 2D 3D TSV |
US10774092 | 345 | 343 | HGNC:12558 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES; SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE; YALE UNIVERSITY | 04/25/21 | 2D 3D TSV |
US10759805 | 43 | 43 | HGNC:6871 | Compounds that are ERK inhibitors | Merck Sharp & Dohme Corp. | 04/19/21 | 2D 3D TSV |
US10759799 | 40 | 20 | HGNC:4617 HGNC:3091 | Indazole containing macrocycles and therapeutic uses thereof | Samumed, LLC | 04/19/21 | 2D 3D TSV |
US10759813 | 222 | 220 | HGNC:7154 | Neprilysin inhibitors | Theravance Biopharma R&D IP, LLC | 04/19/21 | 2D 3D TSV |
US10759812 | 26 | 15 | HGNC:85 HGNC:84 | Thienopyrimidine derivative and use thereof in medicine | Sunshine Lake Pharma Co., Ltd. | 04/19/21 | 2D 3D TSV |
US10759793 | 318 | 106 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | Almirall, S.A. | 04/18/21 | 2D 3D TSV | |
US10759794 | 172 | 77 | HGNC:6283 HGNC:6278 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | BAYER PHARMA AKTIENGESELLSCHAFT | 04/18/21 | 2D 3D TSV |
US10759787 | 43 | 33 | Benzofuran derivative, preparation method thereof and use thereof in medicine | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 04/18/21 | 2D 3D TSV | |
US10759796 | 139 | 138 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. | 04/18/21 | 2D 3D TSV | |
US10759792 | 26 | 26 | CaMKII inhibitors and uses thereof | The Johns Hopkins University | 04/18/21 | 2D 3D TSV | |
US10759777 | 138 | 138 | HGNC:8846 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Synchronicity Pharma, Inc. | 04/18/21 | 2D 3D TSV |
US10758530 | 28 | 20 | HGNC:10435 HGNC:10431 HGNC:10430 HGNC:10432 | Carboxamide derivatives useful as rsk inhibitors | PHOENIX MOLECULAR DESIGNS | 04/18/21 | 2D 3D TSV |
US10759766 | 58 | 32 | HGNC:6307 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. | 04/18/21 | 2D 3D TSV |
US10759769 | 46 | 46 | HGNC:12524 | Glucosylceramide synthase inhibitors for the treatment of diseases | TBA | 04/18/21 | 2D 3D TSV |
US10759791 | 104 | 24 | HGNC:7872 | Mammalian and bacterial nitric oxide synthase inhibitors | Northwestern University | 04/18/21 | 2D 3D TSV |
US10759788 | 6 | 2 | HGNC:6251 HGNC:6255 | Pharmaceutical uses of pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD.; SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. | 04/18/21 | 2D 3D TSV |
US10758542 | 530 | 232 | HGNC:8031 HGNC:12440 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharma Inc. | 04/18/21 | 2D 3D TSV |
US10758539 | 7 | 7 | HGNC:6307 | Therapeutic compounds and uses thereof | Kala Pharmaceuticals, Inc. | 04/18/21 | 2D 3D TSV |
US10745383 | 8 | 8 | 1,3,5-triazine derivative and method of using same | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd.; Centaurus Biopharma Co., Ltd. | 04/13/21 | 2D 3D TSV | |
US10744128 | 140 | 66 | HGNC:4617 HGNC:3091 | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof | Samumed, LLC | 04/13/21 | 2D 3D TSV |
US10744125 | 24 | 6 | HGNC:268 HGNC:262 HGNC:263 HGNC:264 | Adenosine A3 receptor modulators | Palobiofarma, S.L. | 04/13/21 | 2D 3D TSV |
US10745392 | 57 | 19 | HGNC:10593 HGNC:10585 HGNC:10596 | Benzenesulfonamide compounds and their use as therapeutic agents | Xenon Pharmaceuticals Inc. | 04/13/21 | 2D 3D TSV |
US10745401 | 582 | 190 | HGNC:3023 HGNC:5286 | Condensed lactam derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. | 04/13/21 | 2D 3D TSV |
US10745399 | 334 | 57 | HGNC:8978 HGNC:795 HGNC:8975 HGNC:3942 HGNC:8977 HGNC:8976 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | Merck Patent GmbH | 04/13/21 | 2D 3D TSV |
US10745388 | 16 | 16 | HGNC:6863 | Indazole compounds and uses thereof | Incyte Corporation | 04/13/21 | 2D 3D TSV |
US10745380 | 2 | 2 | HGNC:10894 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD | 04/13/21 | 2D 3D TSV |
US10745410 | 18 | 18 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | ZENJI RESEARCH LABORATORIES | 04/13/21 | 2D 3D TSV | |
US10745364 | 424 | 420 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | Lycera Corporation; Merck Sharp & Dohme Corp. | 04/13/21 | 2D 3D TSV | |
US10745420 | 101 | 96 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | Board of Regents, The University of Texas System; ChemPartner Corporation | 04/13/21 | 2D 3D TSV | |
US10744104 | 41 | 40 | HGNC:7154 | Neprilysin inhibitors | Theravance Biopharma R&D IP, LLC | 04/12/21 | 2D 3D TSV |
US10744117 | 5 | 5 | HGNC:9236 | PPARG modulators for the treatment of osteoporosis | The Scripps Research Institute; The University of Toledo | 04/12/21 | 2D 3D TSV |
US10752581 | 86 | 75 | HGNC:429 HGNC:433 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | Eastern Virginia Medical School; The Regents of the University of California Santa; The United States of America Department of Health; Thomas Jefferson University | 04/11/21 | 2D 3D TSV |
US10752632 | 6 | 6 | HGNC:7056 | 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds | Eli Lilly and Company | 04/11/21 | 2D 3D TSV |
US10752598 | 20 | 20 | Aryldiazepine derivatives as RSV inhibitors | Enanta Pharmaceuticals, Inc. | 04/11/21 | 2D 3D TSV | |
US10752616 | 136 | 46 | HGNC:9864 HGNC:9866 HGNC:9865 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | King''s College London | 04/11/21 | 2D 3D TSV |
US10752604 | 35 | 20 | HGNC:11037 HGNC:11036 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | Je II Pharmaceutical Co., Ltd. | 04/11/21 | 2D 3D TSV |
US10752613 | 21 | 15 | HGNC:12805 HGNC:17989 | Compounds and their use for reducing uric acid levels | Acquist LLC | 04/11/21 | 2D 3D TSV |
US10752588 | 28 | 27 | HGNC:3023 | Dopamine D2 receptor ligands | The Broad Institute, Inc.; Massachusetts Institute of Technology | 04/11/21 | 2D 3D TSV |
US10752623 | 196 | 62 | HGNC:10593 HGNC:10585 HGNC:10596 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | Xenon Pharmaceuticals Inc. | 04/11/21 | 2D 3D TSV |
US10752631 | 37 | 12 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Heterocyclic compounds as FGFR inhibitors | Guangzhou Innocare Pharma Tech Co., Ltd. | 04/11/21 | 2D 3D TSV |
US10752626 | 25 | 25 | Iso-citrate dehydrogenase (IDH) inhibitor | SHANGHAI METON PHARMACEUTICAL CO., LTD | 04/11/21 | 2D 3D TSV | |
US10752592 | 113 | 38 | HGNC:8156 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED | 04/11/21 | 2D 3D TSV |
US10752596 | 153 | 152 | Nitrogen-containing heteroaryl compound and pharmaceutical use thereof | JAPAN TOBACCO INC. | 04/11/21 | 2D 3D TSV | |
US10751335 | 60 | 28 | HGNC:8156 | Signaling-biased mu opioid receptor agonists | THE SCRIPPS RESEARCH INSTITUTE | 04/11/21 | 2D 3D TSV |
US10752615 | 526 | 148 | HGNC:1133 HGNC:6171 HGNC:11719 HGNC:12434 | Spirocyclic containing compounds and pharmaceutical uses thereof | GB005, Inc. | 04/11/21 | 2D 3D TSV |
US10751339 | 55 | 14 | HGNC:8979 HGNC:8978 HGNC:6251 | Substituted aminopyrimidine compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD.; CALITOR SCIENCES, LLC | 04/11/21 | 2D 3D TSV |
US10738015 | 84 | 42 | HGNC:8155 HGNC:8156 | 1,3-diaza-spiro-[3.4]-octane derivatives | GRÜNENTHAL GMBH | 04/04/21 | 2D 3D TSV |
US10738063 | 246 | 64 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | Pfizer Inc. | 04/04/21 | 2D 3D TSV | |
US10738007 | 130 | 97 | HGNC:10251 HGNC:10252 | Amide compounds as kinase inhibitors, compositions and methods of treatment | Translation Drug Development, LLC | 04/04/21 | 2D 3D TSV |
USRE48150 | 34 | 33 | HGNC:6857 | Apoptosis signal-regulating kinase inhibitors | Gilead Sciences, Inc. | 04/04/21 | 2D 3D TSV |
US10736881 | 141 | 96 | HGNC:4852 HGNC:13315 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI Pharma, Inc. | 04/04/21 | 2D 3D TSV |
US10738053 | 42 | 4 | HGNC:1373 HGNC:10548 | Bicyclic compounds as dual ATX/CA inhibitors | Hoffmann-La Roche Inc. | 04/04/21 | 2D 3D TSV |
US10738048 | 152 | 37 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 04/04/21 | 2D 3D TSV |
US10738074 | 43 | 29 | Cyclic di-nucleotide compounds as STING agonists | Merck Sharp & Dohme Corp. | 04/04/21 | 2D 3D TSV | |
US10738052 | 205 | 204 | HGNC:7029 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION | 04/04/21 | 2D 3D TSV |
US10738026 | 17 | 11 | HGNC:10597 | Isoquinoline derivatives and use thereof | Purdue Pharma L.P. | 04/04/21 | 2D 3D TSV |
US10736890 | 75 | 37 | HGNC:8156 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED | 04/04/21 | 2D 3D TSV |
US10738056 | 517 | 508 | Pyrazolopyrimidinone compounds and uses thereof | Aduro BioTech Inc. | 04/04/21 | 2D 3D TSV | |
US10738009 | 160 | 158 | HGNC:10582 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 04/04/21 | 2D 3D TSV |
US10736974 | 64 | 35 | HGNC:3788 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSITY | 04/04/21 | 2D 3D TSV |
US10738057 | 246 | 118 | HGNC:8978 HGNC:8977 | Tertiary alcohols as PI3K-γ inhibitors | Incyte Corporation | 04/04/21 | 2D 3D TSV |
US10736883 | 326 | 315 | HGNC:339 | Triazole furan compounds as agonists of the APJ receptor | AMGEN INC. | 04/04/21 | 2D 3D TSV |
US10723742 | 270 | 242 | HGNC:29079 | Biphenyl compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 03/30/21 | 2D 3D TSV |
US10730902 | 10 | 5 | HGNC:6561 HGNC:6563 | 1,1 ′-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins | GALECTO BIOTECH AB | 03/28/21 | 2D 3D TSV |
US10730889 | 403 | 380 | HGNC:30092 | Amido spirocyclic amide and sulfonamide derivatives | FORMA TM, LLC; Genentech, Inc. | 03/28/21 | 2D 3D TSV |
US10723734 | 237 | 230 | HGNC:19679 | Biaryl kinase inhibitors | Bristol-Myers Squibb Company | 03/28/21 | 2D 3D TSV |
US10722495 | 51 | 51 | HGNC:6863 | Cyanoindazole compounds and uses thereof | Incyte Corporation | 03/28/21 | 2D 3D TSV |
US10722597 | 33 | 4 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | Cyclodextrin-panobinostat adduct | MIDATECH LTD. | 03/28/21 | 2D 3D TSV |
US10722489 | 10 | 10 | HGNC:8923 | D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof | Peking University | 03/28/21 | 2D 3D TSV |
US10723705 | 206 | 204 | HGNC:13315 | Heterocyclic compounds and uses thereof | Incyte Corporation | 03/28/21 | 2D 3D TSV |
US10723709 | 26 | 6 | HGNC:2536 HGNC:2537 HGNC:2545 | Protease inhibitors | MEDIVIR AB | 03/28/21 | 2D 3D TSV |
US10723723 | 220 | 173 | HGNC:6255 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | Bristol-Myers Squibb Company | 03/28/21 | 2D 3D TSV |
US10730882 | 34 | 34 | HGNC:10436 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LIMITED | 03/27/21 | 2D 3D TSV |
US10730880 | 867 | 199 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | Array BioPharma Inc.; Celgene Corporation | 03/27/21 | 2D 3D TSV |
US10730877 | 3210 | 841 | HGNC:15633 HGNC:15631 HGNC:15632 | 4-Azaindole compounds | Bristol-Myers Squibb Company | 03/27/21 | 2D 3D TSV |
US10730868 | 104 | 95 | HGNC:3540 | Bicyclic heteroaryl substituted compounds | Bristol-Myers Squibb Company | 03/27/21 | 2D 3D TSV |
US10730870 | 267 | 140 | HGNC:12687 | Compounds and methods for the enhanced degradation of targeted proteins | ARVINAS OPERATIONS, INC.; YALE UNIVERSITY | 03/27/21 | 2D 3D TSV |
US10730865 | 49 | 49 | Compounds for modulating aquaporins | APOGLYX AB | 03/27/21 | 2D 3D TSV | |
US10730860 | 3 | 2 | HGNC:13575 | Diaminopyrimidine benzenesulfone derivatives and uses thereof | Dana-Farber Cancer Institute, Inc. | 03/27/21 | 2D 3D TSV |
US10730881 | 28 | 28 | HGNC:620 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE, INC. | 03/27/21 | 2D 3D TSV |
US10730866 | 84 | 72 | HGNC:10597 | Indole derivatives and use thereof | Purdue Pharma L.P. | 03/27/21 | 2D 3D TSV |
US10730874 | 328 | 296 | HGNC:6371 | Inhibitors of plasma kallikrein and uses thereof | Shire Human Genetic Therapies, Inc. | 03/27/21 | 2D 3D TSV |
US10730875 | 135 | 31 | HGNC:6190 HGNC:6192 HGNC:12440 | Substituted imidazo[1,2-A]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | JN Therapeutics | 03/27/21 | 2D 3D TSV |
US10729680 | 63 | 63 | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT | 03/21/21 | 2D 3D TSV | |
US10730832 | 130 | 130 | Aliphatic prolinamide derivatives | ORION OPHTHALMOLOGY LLC | 03/21/21 | 2D 3D TSV | |
US10729684 | 24 | 12 | HGNC:10597 | Alkynyl dihydroquinoline sulfonamide compounds | AMGEN INC. | 03/21/21 | 2D 3D TSV |
US10729695 | 29 | 29 | HGNC:320 | Amino, amido and heterocyclic compounds as modulators of RAGE activity and uses thereof | The Research Foundation for the State University of New York; New York University | 03/21/21 | 2D 3D TSV |
US10730856 | 12 | 12 | HGNC:9596 | Benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT | 03/21/21 | 2D 3D TSV |
US10730849 | 95 | 51 | Benzo[b]thiophene compounds as STING agonists | Merck Sharp & Dohme Corp. | 03/21/21 | 2D 3D TSV | |
US10730863 | 435 | 427 | HGNC:7967 | Bridged bicyclic compounds as farnesoid X receptor modulators | Bristol-Myers Squibb Company | 03/21/21 | 2D 3D TSV |
US10729710 | 17 | 6 | HGNC:3023 HGNC:3020 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | H. Lundbeck A/S | 03/21/21 | 2D 3D TSV |
US10717746 | 178 | 86 | HGNC:1780 | Chemical compounds | ASTRAZENECA AB | 03/21/21 | 2D 3D TSV |
US10730853 | 36 | 17 | HGNC:5184 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XW LABORATORIES INC. | 03/21/21 | 2D 3D TSV |
US10717737 | 116 | 115 | HGNC:29079 | Cyclopropylamines as LSD1 inhibitors | Incyte Corporation | 03/21/21 | 2D 3D TSV |
US10717733 | 462 | 116 | HGNC:6834 HGNC:550 HGNC:6666 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | Pharmaxis Ltd. | 03/21/21 | 2D 3D TSV |
US10717734 | 176 | 44 | HGNC:6834 HGNC:550 HGNC:6666 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | Pharmaxis Ltd. | 03/21/21 | 2D 3D TSV |
US10716791 | 42 | 17 | HGNC:18367 HGNC:18368 | Inhibitors of peptidyl arginine deiminase (PAD) enzymes and uses thereof | University Health Network | 03/21/21 | 2D 3D TSV |
US10730826 | 181 | 68 | HGNC:2531 HGNC:2538 HGNC:2527 HGNC:2536 HGNC:2547 HGNC:2537 HGNC:2545 HGNC:2535 | Ketone inhibitors of lysine gingipain | CORTEXYME, INC. | 03/21/21 | 2D 3D TSV |
US10717708 | 62 | 31 | HGNC:3827 HGNC:3826 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | Bristol-Myers Squibb Company | 03/21/21 | 2D 3D TSV |
US10730850 | 106 | 106 | HGNC:550 | Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | Boehringer Ingelheim International GmbH | 03/21/21 | 2D 3D TSV |
US10717738 | 29 | 29 | HGNC:3529 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. | 03/21/21 | 2D 3D TSV |
US10717742 | 148 | 137 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Boehringer Ingelheim International GmbH | 03/21/21 | 2D 3D TSV | |
US10730833 | 9 | 9 | HGNC:348 | Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them | Wisconsin Alumni Research Foundation | 03/21/21 | 2D 3D TSV |
US10730830 | 51 | 25 | HGNC:3165 HGNC:14299 | Tetrahydronaphthalene derivative | ONO PHARMACEUTICAL CO., LTD. | 03/21/21 | 2D 3D TSV |
US10717764 | 402 | 207 | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. | 03/21/21 | 2D 3D TSV | |
US10729691 | 118 | 59 | HGNC:11005 | Treatment of infectious diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC | 03/21/21 | 2D 3D TSV |
US10711036 | 87 | 87 | HGNC:6819 | MALT1 inhibitors and uses thereof | Cornell University; Dana-Farber Cancer Institute, Inc.; Children''s Medical Center Corporation | 03/15/21 | 2D 3D TSV |
US10711006 | 65 | 28 | HGNC:4840 HGNC:3697 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:2444 HGNC:3765 | Selective Bruton's tyrosine kinase inhibitor and use thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. | 03/15/21 | 2D 3D TSV |
US10711007 | 49 | 49 | HGNC:10894 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | Prelude Therapeutics Incorporated | 03/15/21 | 2D 3D TSV |
US10711020 | 881 | 783 | Tricyclic sulfones as RORγ modulators | Bristol-Myers Squibb Company | 03/15/21 | 2D 3D TSV | |
US10709688 | 40 | 16 | HGNC:3559 HGNC:3557 | Agent for treating synucleinopathy | Tohoku University; National University Corporation Okayama University | 03/14/21 | 2D 3D TSV |
US10710980 | 616 | 88 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | Novartis AG | 03/14/21 | 2D 3D TSV | |
US10709712 | 2614 | 1072 | HGNC:9829 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG | 03/14/21 | 2D 3D TSV |
US10709695 | 2 | 2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 03/14/21 | 2D 3D TSV | |
US10709718 | 28 | 28 | HGNC:2843 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof | Metabasis Therapeutics, Inc. | 03/14/21 | 2D 3D TSV |
US10710994 | 297 | 150 | HGNC:497 | Oxadiazole transient receptor potential channel inhibitors | Genentech, Inc. | 03/14/21 | 2D 3D TSV |
US10711004 | 455 | 275 | HGNC:497 | Oxadiazole transient receptor potential channel inhibitors | Genentech, Inc. | 03/14/21 | 2D 3D TSV |
US10710986 | 657 | 656 | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. | 03/14/21 | 2D 3D TSV | |
US10710967 | 299 | 294 | HGNC:9599 | Pyrimidine derivative | ASKA PHARMACEUTICAL CO., LTD. | 03/14/21 | 2D 3D TSV |
US10710978 | 234 | 59 | HGNC:11403 HGNC:11408 HGNC:18174 HGNC:11406 | STK4 inhibitors for treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC.; FONDAZIONE CENTRO SAN RAFFAELE | 03/14/21 | 2D 3D TSV |
US10709719 | 42 | 10 | HGNC:3167 HGNC:3165 | Substituted bicyclic compounds | Bristol-Myers Squibb Company | 03/14/21 | 2D 3D TSV |
US10709709 | 212 | 203 | HGNC:10894 | Substituted carbonucleoside derivatives useful as anticancer agents | Pfizer Inc. | 03/14/21 | 2D 3D TSV |
US10676499 | 33 | 17 | HGNC:3287 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG | 03/11/21 | 2D 3D TSV |
US10676464 | 43 | 43 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University Of The Commonwealth System of Higher Education | 03/11/21 | 2D 3D TSV | |
US10676458 | 17 | 11 | HGNC:4498 | Antidiabetic bicyclic compounds | Merch Sharp & Dohne Corp. Rahway | 03/11/21 | 2D 3D TSV |
US10676467 | 113 | 58 | HGNC:3169 HGNC:3167 HGNC:3165 HGNC:14299 HGNC:3170 | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof | Washington University | 03/11/21 | 2D 3D TSV |
US10676457 | 130 | 129 | HGNC:29079 | Cyclopropylamines as LSD1 inhibitors | Incyte Corporation | 03/11/21 | 2D 3D TSV |
US10676465 | 188 | 94 | HGNC:4324 | GLP-1 receptor agonists and uses thereof | Pfizer Inc. | 03/11/21 | 2D 3D TSV |
US10676479 | 360 | 118 | HGNC:17101 | Imidazolepyridine compounds and uses thereof | Novartis AG | 03/11/21 | 2D 3D TSV |
US10676470 | 36 | 34 | Inhibitors of lysine gingipain | CORTEXYME, INC. | 03/11/21 | 2D 3D TSV | |
US10676469 | 383 | 182 | HGNC:8154 HGNC:8156 | Kappa opioid receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC.; THE SCRIPPS RESEARCH INSTITUTE | 03/11/21 | 2D 3D TSV |
US10676485 | 106 | 53 | HGNC:6943 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Inc. | 03/11/21 | 2D 3D TSV |
US10676460 | 56 | 3 | HGNC:9077 HGNC:11283 HGNC:11584 HGNC:14552 HGNC:17967 HGNC:12434 HGNC:11724 HGNC:6735 HGNC:2451 HGNC:5465 HGNC:4617 HGNC:2459 HGNC:6112 HGNC:2457 HGNC:3767 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:6171 HGNC:11390 HGNC:12440 HGNC:1079 HGNC:1771 HGNC:1133 HGNC:6860 HGNC:7972 HGNC:6524 HGNC:1775 | Quinazolines as potassium ion channel inhibitors | Bristol-Myers Squibb Company | 03/11/21 | 2D 3D TSV |
US10676476 | 30 | 14 | HGNC:3430 HGNC:5253 | Small-molecule HSP90 inhibitors | Sloan-Kettering Institute for Cancer Research | 03/11/21 | 2D 3D TSV |
US10676446 | 190 | 190 | HGNC:3357 | Bicyclic quinazolinone derivatives | Hoffmann-La Roche Inc. | 03/10/21 | 2D 3D TSV |
US10676434 | 200 | 178 | HGNC:1133 | Carbazole derivatives | Bristol-Myers Squibb Company | 03/10/21 | 2D 3D TSV |
US10675286 | 612 | 109 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. | 03/10/21 | 2D 3D TSV |
US10676433 | 355 | 196 | HGNC:5992 HGNC:8537 | Indole derivatives and their use in neurodegenerative diseases | Merck Patent GmbH | 03/10/21 | 2D 3D TSV |
US10676438 | 16 | 10 | HGNC:6251 | KCNQ2-5 channel activator | Ono Pharmaceutical Co., Ltd. | 03/10/21 | 2D 3D TSV |
US10676431 | 270 | 127 | HGNC:3827 HGNC:3826 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | Bristol-Myers Squibb Company | 03/10/21 | 2D 3D TSV |
US10675268 | 284 | 169 | HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 | Somatostatin receptor subtype 4 (SSTR4) agonists | Centrexion Therapeutics Corporation | 03/10/21 | 2D 3D TSV |
US10675284 | 37 | 37 | HGNC:6190 HGNC:8977 | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | Incyte Corporation | 03/10/21 | 2D 3D TSV |
US10703751 | 36 | 7 | HGNC:6192 HGNC:6193 | Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof | Leo Pharma A/S | 03/08/21 | 2D 3D TSV |
US10703741 | 26 | 16 | HGNC:18368 | Covalent inhibitors of PAD4 | Padlock Therapeutics, Inc. | 03/08/21 | 2D 3D TSV |
US10702504 | 21 | 21 | HGNC:11812 | Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. | 03/08/21 | 2D 3D TSV |
US10703733 | 457 | 445 | MCL-1 inhibitors | Gilead Sciences, Inc. | 03/08/21 | 2D 3D TSV | |
US10702498 | 27 | 15 | HGNC:8154 HGNC:8156 | MU opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN-NÜRNBERG; THE BOARD OF TRUSTEES OFTHE LELAND STANFORD JUNIOR UNIVERSITY; THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 03/08/21 | 2D 3D TSV |
US10703749 | 843 | 289 | HGNC:8537 | P2X7 modulators | Janssen Pharmaceutica NV | 03/08/21 | 2D 3D TSV |
US10708263 | 5 | 1 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV | 03/08/21 | 2D 3D TSV | |
US10703740 | 14 | 14 | HGNC:13575 | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | Neomed Institute | 03/08/21 | 2D 3D TSV |
US10703755 | 351 | 337 | HGNC:15631 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. | 03/08/21 | 2D 3D TSV |
US10696692 | 374 | 308 | HGNC:30092 | Amido-benzyl sulfone and sulfoxide derivates | TBA | 03/02/21 | 2D 3D TSV |
US10696672 | 157 | 152 | HGNC:6161 | Amino acid compounds and methods of use | Pliant Therapeutics, Inc. | 03/02/21 | 2D 3D TSV |
US10696682 | 44 | 44 | HGNC:1771 | CDK inhibitors | G1 Therapeutics, Inc. | 03/02/21 | 2D 3D TSV |
US10696661 | 70 | 69 | HGNC:11305 | Compounds | Exonate Limited | 03/02/21 | 2D 3D TSV |
US10696638 | 48 | 43 | HGNC:10251 HGNC:10252 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE | 03/02/21 | 2D 3D TSV |
US10695334 | 98 | 57 | HGNC:6371 HGNC:11830 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | Boehringer Ingelheim International GmbH | 03/02/21 | 2D 3D TSV |
US10696678 | 154 | 64 | HGNC:1722 | Kinase inhibitor, and preparing method and pharmaceutical use thereof | GAN & LEE PHARMACEUTICALS | 03/02/21 | 2D 3D TSV |
US10696665 | 61 | 23 | HGNC:5382 | Mutant IDH1 inhibitors | Eli Lilly and Company | 03/02/21 | 2D 3D TSV |
US10695337 | 794 | 388 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | Incyte Holdings Corporation; Incyte Corporation | 03/02/21 | 2D 3D TSV | |
US10695347 | 84 | 40 | HGNC:427 | Pyrimidine derivative and use thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. | 03/02/21 | 2D 3D TSV |
US10696660 | 91 | 36 | HGNC:10251 HGNC:10252 | Rho kinase inhibitors | Kadmon Corporation, LLC | 03/02/21 | 2D 3D TSV |
US10696689 | 23 | 23 | HGNC:11331 | Somatostatin modulators and uses thereof | CRINETICS PHARMACEUTICALS, INC. | 03/02/21 | 2D 3D TSV |
US10696655 | 125 | 125 | HGNC:2348 | Therapeutic compounds and uses thereof | GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. | 03/02/21 | 2D 3D TSV |
US10689373 | 308 | 149 | HGNC:4849 HGNC:4848 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 02/22/21 | 2D 3D TSV |
US10689345 | 273 | 269 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Mission Therapeutics Limited | 02/22/21 | 2D 3D TSV | |
US10689401 | 50 | 25 | HGNC:934 HGNC:933 | C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp. | 02/22/21 | 2D 3D TSV |
US10689705 | 212 | 71 | HGNC:3690 HGNC:3689 HGNC:3688 | FGFR3 fusion gene and pharmaceutical drug targeting same | Chugai Seiyaku Kabushiki Kaisha | 02/22/21 | 2D 3D TSV |
US10689346 | 302 | 246 | HGNC:6371 | Human plasma kallikrein inhibitors | BioCryst Pharmaceuticals, Inc. | 02/22/21 | 2D 3D TSV |
US10688100 | 52 | 13 | HGNC:10261 | Macrocylic compounds as ROS1 kinase inhibitors | Array BioPharma Inc. | 02/22/21 | 2D 3D TSV |
US10688093 | 708 | 647 | HGNC:4037 | Methods, compositions, and uses of novel Fyn kinase inhibitors | TBA | 02/22/21 | 2D 3D TSV |
US10689357 | 43 | 43 | HGNC:736 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof | NORTHEASTERN UNIVERSITY | 02/22/21 | 2D 3D TSV |
US10689398 | 91 | 89 | HGNC:8157 | OXA-Diazaspiro compounds having activity against pain | ESTEVE PHARMACEUTICALS, S.A. | 02/22/21 | 2D 3D TSV |
USRE48059 | 122 | 64 | Piperazine-substituted benzothiophenes for treatment of mental disorders | Otsuka Pharmaceutical Co., Ltd. | 02/22/21 | 2D 3D TSV | |
US10689327 | 30 | 15 | HGNC:4595 HGNC:4594 | Prodrug amino acid derivative | TAISHO PHARMACEUTICAL CO., LTD. | 02/22/21 | 2D 3D TSV |
US10689339 | 69 | 69 | HGNC:2545 | Pyrrolidine derivatives | Hoffmann-La Roche Inc. | 02/22/21 | 2D 3D TSV |
US10689362 | 508 | 124 | HGNC:8804 HGNC:6342 HGNC:3765 | Quinoxaline compounds as type III receptor tyrosine kinase inhibitors | Development Center for Biotechnology | 02/22/21 | 2D 3D TSV |
US10689399 | 23 | 23 | HGNC:9213 | Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections | Gilead Sciences, Inc. | 02/22/21 | 2D 3D TSV |
US10689369 | 149 | 127 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp. | 02/22/21 | 2D 3D TSV | |
US10689376 | 39 | 39 | HGNC:3356 | Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc.; The University of Utah | 02/22/21 | 2D 3D TSV |
US10689414 | 404 | 206 | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. | 02/22/21 | 2D 3D TSV | |
US10689367 | 327 | 233 | HGNC:339 | Triazole pyridyl compounds as agonists of the APJ receptor | AMGEN INC. | 02/22/21 | 2D 3D TSV |
US10689390 | 18 | 18 | HGNC:13575 | Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer | JUBILANT BIOSYS LIMITED | 02/22/21 | 2D 3D TSV |
US10689395 | 14 | 14 | HGNC:13575 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | JUBILANT BIOSYS LIMITED | 02/22/21 | 2D 3D TSV |
US10669240 | 500 | 242 | HGNC:3091 | 5-substituted indazole-3-carboxamides and preparation and use thereof | Samumed, LLC | 02/21/21 | 2D 3D TSV |
US10669246 | 153 | 115 | HGNC:8803 HGNC:76 HGNC:6342 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. | 02/21/21 | 2D 3D TSV |
US10669268 | 343 | 306 | HGNC:10548 | Bicyclic derivatives | Hoffmann-La Roche Inc. | 02/21/21 | 2D 3D TSV |
US10669289 | 209 | 104 | HGNC:9542 HGNC:9545 | Boronic acid derivatives | MERCK PATENT GMBH | 02/21/21 | 2D 3D TSV |
US10669245 | 37 | 37 | HGNC:2528 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB | 02/21/21 | 2D 3D TSV |
US10669285 | 43 | 43 | HGNC:10548 | Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | Hoffmann-La Roche Inc. | 02/21/21 | 2D 3D TSV |
US10669276 | 48 | 48 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE INC. | 02/21/21 | 2D 3D TSV | |
US10669271 | 94 | 30 | HGNC:7794 HGNC:9644 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 02/21/21 | 2D 3D TSV |
US10669279 | 372 | 104 | HGNC:8780 HGNC:8781 HGNC:8783 | Imidazopyridazine compounds | Pfizer Inc. | 02/21/21 | 2D 3D TSV |
US10669243 | 10 | 10 | Isoxazole carboxamides as irreversible SMYD inhibitors | EPIZYME, INC. | 02/21/21 | 2D 3D TSV | |
US10669296 | 8 | 4 | LXR agonists and uses thereof | Rgenix, Inc. | 02/21/21 | 2D 3D TSV | |
US10669265 | 142 | 72 | HGNC:6307 HGNC:8804 HGNC:9437 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. | 02/21/21 | 2D 3D TSV |
US10669267 | 65 | 39 | HGNC:8537 | Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists | Axxam S.P.A. | 02/21/21 | 2D 3D TSV |
US10669273 | 42 | 36 | HGNC:6059 | Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO | Peking University | 02/21/21 | 2D 3D TSV |
US10683294 | 67 | 67 | HGNC:1338 | 5-5 fused rings as C5a inhibitors | ChemoCentryx, Inc. | 02/16/21 | 2D 3D TSV |
US10683295 | 59 | 29 | HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof | Ogeda SA | 02/16/21 | 2D 3D TSV |
US10683291 | 3 | 3 | HGNC:3165 | Heterocyclic compounds for the treatment of disease | OPPILAN PHARMA LTD. | 02/16/21 | 2D 3D TSV |
US10683290 | 84 | 80 | Tricyclic compounds as anticancer agents | Bristol-Myers Squibb Company | 02/16/21 | 2D 3D TSV | |
US10683309 | 84 | 42 | HGNC:12008 HGNC:20692 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN; FORSCHUNGSVERBUND BERLIN E.V. | 02/16/21 | 2D 3D TSV |
US10668071 | 105 | 100 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT | 02/15/21 | 2D 3D TSV | |
US10667515 | 17 | 17 | (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using | Iowa State University Research Foundation, Inc. | 02/15/21 | 2D 3D TSV | |
US10683279 | 71 | 68 | HGNC:6857 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 02/15/21 | 2D 3D TSV |
US10683289 | 23 | 23 | HGNC:6857 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 02/15/21 | 2D 3D TSV |
US10682352 | 117 | 100 | HGNC:5382 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 02/15/21 | 2D 3D TSV |
US10669227 | 24 | 9 | HGNC:7175 HGNC:7176 HGNC:7166 HGNC:7159 | Curcumin analogues as zinc chelators and their uses | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 02/15/21 | 2D 3D TSV |
US10669234 | 193 | 147 | HGNC:12513 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED | 02/15/21 | 2D 3D TSV |
US10668167 | 176 | 62 | HGNC:7978 HGNC:644 HGNC:3467 HGNC:8910 | Glucocorticoid receptor agonist and immunoconjugates thereof | AbbVie Inc. | 02/15/21 | 2D 3D TSV |
US10683287 | 96 | 45 | HGNC:934 HGNC:933 | Heterocyclic derivatives and their use in the treatment of neurological disorders | Novartis AG | 02/15/21 | 2D 3D TSV |
US10669235 | 336 | 55 | HGNC:8803 HGNC:3763 HGNC:6307 HGNC:8804 HGNC:3690 HGNC:3688 | Indole derivatives and their use as protein kinase inhibitors | RESPIVERT LIMITED | 02/15/21 | 2D 3D TSV |
US10668051 | 56 | 56 | HGNC:25896 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA | 02/15/21 | 2D 3D TSV |
US10668033 | 4 | 4 | HGNC:9602 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 02/15/21 | 2D 3D TSV |
US10668067 | 135 | 135 | HGNC:10597 | Pyridine sulfonamides | AMGEN INC. | 02/15/21 | 2D 3D TSV |
US10668094 | 92 | 21 | Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure | Yeda Research and Development Co. Ltd. | 02/15/21 | 2D 3D TSV | |
US10669239 | 74 | 68 | HGNC:8031 | Tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. | 02/15/21 | 2D 3D TSV |
US10660877 | 2542 | 841 | HGNC:15633 HGNC:15631 HGNC:15632 | Pyridyl substituted indole compounds | Bristol-Myers Squibb Company | 02/08/21 | 2D 3D TSV |
US10662159 | 204 | 60 | HGNC:3553 HGNC:17038 HGNC:21398 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | MAKSCIENTIFIC, LLC | 02/07/21 | 2D 3D TSV |
US10660876 | 90 | 89 | HGNC:2771 | Amino compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. | 02/07/21 | 2D 3D TSV |
US10662184 | 150 | 83 | HGNC:10593 HGNC:10585 HGNC:10596 | Benzenesulfonamide compounds and their use as therapeutic agents | Xenon Pharmaceuticals Inc. | 02/07/21 | 2D 3D TSV |
US10660898 | 27 | 27 | HGNC:8972 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC | 02/07/21 | 2D 3D TSV |
US10662187 | 134 | 124 | HGNC:6735 HGNC:1057 HGNC:1133 HGNC:3236 HGNC:6524 | Bruton's tyrosine kinase inhibitors | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd.; Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 02/07/21 | 2D 3D TSV |
US10662156 | 94 | 90 | HGNC:6819 | Guanidine derivative and medical use thereof | Toray Industries, Inc. | 02/07/21 | 2D 3D TSV |
US10662189 | 84 | 78 | HGNC:8781 | PDE4 inhibitor | SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD. | 02/07/21 | 2D 3D TSV |
US10662186 | 650 | 137 | HGNC:1780 HGNC:1771 HGNC:1778 HGNC:1722 HGNC:1777 HGNC:1774 HGNC:1773 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. | 02/07/21 | 2D 3D TSV |
US10654833 | 96 | 90 | HGNC:6857 | ASK1 isoindolin-1-one inhibitors and methods of use thereof | Hepatikos Therapeutics, LLC | 02/01/21 | 2D 3D TSV |
US10654857 | 68 | 7 | HGNC:10555 | Bicyclic compounds as autotaxin (ATX) and lysophosphati |